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Glioblastoma is the most common and aggressive primary brain tumor in adults. Median 
survival is no more than 15 months, even with combined treatment regimens. The lack of 
accurate pre-clinical model systems has limited the development of new treatment options for 
this deadly disease.  
In the first study we set out with the goal of creating improved research models for studying 
the disease. To this end we generated a glioblastoma patient derived cell line (PDCL) library. 
PDCLs grown under neural stem cell conditions functionally isolate glioblastoma cells with 
stem-like properties. In keeping with their cancer stem cell like nature PDCLs readily formed 
patient derived xenografts (PDXs) when transplanted in vivo, recapitulating histological 
features and maintaining genetic/protein profiles of founding tumors. Expression profiling of 
PDCLs revealed 4 in vitro subclasses differentially associated with WNT/B-catenin, TGF-B, 
BMP, Interferon, Notch and p53 signaling. Applying these new in vitro PDCL-classes to 
glioblastoma patient data generated clinically relevant subclasses with differences in age and 
survival. Hence, new PDCL models represent the original disease including aspects such as 
genomics/proteomics, intratumoral heterogeneity and cancer stem cell biology. In addition to 
functional isolation of stem-like cells using PDCL methods there have been several proteins 
proposed to distinguish cancer stem cells (CSCs). The most popular such protein is Prominin-
1 (PROM1/CD133). In the second study we investigated Prominin-1 expression in the 
developing CNS and glioblastoma. Prominin-1 is expressed in the ventricular zone of the 
embryonic brain and postnatally shifts to a pattern of distributed cells. The adult murine 
Prom1+ cell population mainly consists of Olig2+ slow cycling glial cells. Further, we 
established that Prom1 is independent of Olig2. Human normal brain PROM1 is associated 
with GFAP and SOX2. In glioblastoma PDCLs PROM1+ cells can express GFAP, SOX2 and 
OLIG2. PROM1 patterns are very heterogeneous across PDCLs and patient samples revealed 
that high PROM1 expression is less common in IDH1 mutant samples. In the third and fourth 
studies we investigated the possible functions of NPM1 in glioblastoma. NPM1 is a nucleolar 
chaperone protein highly upregulated in glioblastoma tissue samples and cell lines. We 
showed that NPM1 regulated the morphology of the nucleolus. This is likely due to NPM1 
interacting with proteins implicated in the organization of chromatin such as HP1γ, H1.5 and 
H3. We also found that NPM1/DNMT3A co-depletion induced rDNA transcription and 
nucleolar normalization. Although DNMT3A loss upregulated rDNA transcription on its own 
depletion of NPM1 increased this effect suggesting NPM1 loss creates a permissive 
environment for further epigenetic change. NPM1 depletion sensitized glioblastoma cell lines 
to chemotherapy and further insults to chromatin stability such as the co-depletion of H1.5, 
implying NPM1 as a novel drug target. 
This thesis characterizes a glioblastoma PDCL library, illustrating the benefits of these new 
research models and addresses the complex expression of Prominin-1 and function of NPM1 
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1 INTRODUCTION 
Gliomas are tumors of the central nervous system (CNS) with glioblastoma (GBM) being the 
most common high-grade (grade IV) malignant glioma in adults (Louis et al. 2007). 
Glioblastoma has a terrible prognosis, median survival is not more than 12-15 months even 
with combined treatment regimens (Stupp et al. 2005; Louis et al. 2007; Van Meir et al. 
2010). Chemotherapy (temozolomide based) and radiotherapy have insufficient effects on 
these tumors. Surgical treatment only offers temporary relief due to the highly infiltrative 
growth of the tumor cells and the negative effects of removing surrounding neural tissue, 
making it impossible to achieve complete tumor resection. Even when all of these methods 
are combined relapse is imminent. Not only do all patients relapse but there is also a trend of 
increased malignancy in the recurring tumor (Kang and Kang 2007; TCGA 2008; van Thuijl 
et al. 2015). The main problem is the fact that all tumor cells with the ability to regenerate the 
tumor are not removed/ablated by the treatments. These cells have been termed cancer stem 
cells (CSCs) and tumor initiating cells (TICs) with the glioma specific variants of the terms 
being glioma stem cells (GSCs) and glioma initiating cells (GICs) (Singh et al. 2003; 
Sakariassen et al. 2007; Griffero et al. 2009; Anido et al. 2010). For this thesis I will use the 
term cancer stem cells (CSCs). CSCs are described in several types of cancers and it is not a 
phenomenon restricted to CNS malignancies (Huang and Wicha 2008; Maitland and Collins 
2008; Peacock and Watkins 2008). The cells of origin for gliomas are unknown. CSCs may 
be of particular interest to understand these origins, since it’s believed that they could be the 
founding cells of the tumor. Finding the glioblastoma cell of origin in the normal tissue might 
give important clues on how to better tackle glioblastomas with new innovative treatments, 
whilst sparing normal brain structures.  
Despite its rarity glioblastoma has during recent years been a leading model for the study of 
cancer, being the first disease selected to be characterized by The Cancer Genome Atlas 
(TCGA) due to its fast progression, limited treatment options and dismal survival rates. This 
has given us detailed knowledge about the genomic landscapes and molecular subclasses of 
glioblastoma (Verhaak et al. 2010; Brennan et al. 2013). These and other studies reveal very 
high degrees of tumor heterogeneity at genome, gene expression and protein levels including 
within and across patients. (Snuderl et al. 2011; Patel et al. 2014). Glioblastoma has also been 
one of the main cancers involved in the development of the re-emerging theory about CSCs, 
where PROM1 (Prominin-1/CD133) has been described as a prospective marker for 
identification and isolation of CSCs (Singh et al. 2003). The parallels drawn between the 
varying spectrum and degrees of differentiation in CSCs and neural stem cells (NSCs) are 
intriguing with possible application in tumor progression and tumor growth. DNA 
methylation and histone methylation/acetylation are other factors involved in regulating the 
cell state and dictating gene expression and consequently the differentiation of the cell (Jones 
and Baylin 2007). This controls the process of normal development and cell turnover in 
mature tissue as well as playing key roles in cancer (Bernstein et al. 2006). New methods for 
culturing normal CNS cells have also greatly helped the glioblastoma field, giving 
researchers a new generation of patient derived cell lines (PDCLs) able to maintain key 
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genetic alterations and mRNA/protein expression patterns found in the primary disease better 
than was possible in the last 50 years using conventional serum cultured cell lines (Hodgson 
et al. 2009; Wakimoto et al. 2011). These new cell models together with today’s vast options 
in biological screens have opened the door for the more effective development of new 
targeted treatments. However, more work to develop methods, characterize the models and 
study the biology is needed to realize this potential. 
1.1 NEURAL STEM AND PROGENITOR CELLS 
With regards to gliomas, neural stem/progenitor cells hold great interest due to their possible 
roles as cells of origin, overlap in signaling pathways/transcriptional networks and 
phenotypic/proteomic similarities that may shed light on how to treat these tumors. Thus, 
NSC biology can be considered a foundation on which to base glioma/brain tumor biology. 
Following is a brief description of neural stem/progenitor cells with focus on cells and 
markers often implied in brain tumor biology.  
1.1.1 Neural stem cells 
There are a number of regions in the embryonic and adult brain that harbor neural stem cells 
(NSCs) in human and murine systems (Fuentealba et al. 2012; Florio and Huttner 2014; Lim 
and Alvarez-Buylla 2014). NSCs are multipotent and can generate all the three main cell 
types of the brain, i.e. neurons, astrocytes and oligodendrocytes. NSCs can be cultured in 
vitro where single NSCs proliferate and form spheres, known as neurospheres (Reynolds and 
Weiss 1992; Rietze and Reynolds 2006). No single marker protein can prospectively 
distinguish a NSC from other cells of the brain, but the proteins NESTIN, PROM1, GFAP, 
OLIG2, GFAPδ and SOX2 have emerged as useful markers (Uchida et al. 2000; Ellis et al. 
2004; Roelofs et al. 2005; Menn et al. 2006; Ligon et al. 2007; van den Berge et al. 2010; 
Codega et al. 2014). Differentiated neural cell types can be identified with their own set of 
markers; oligodendrocytes can be identified by the markers CNPase and O4, astrocytes by 
GFAP and S100B whereas neurons are positive for TUJ1 and NeuN. Said markers are also 
used in differentiation assays of NSCs confirming multipotency (Uchida et al. 2000; Lee et 
al. 2005). Using several of these markers together can then allow further mapping of cell 
identities and differentiation stages.    
During embryonic development there is an extensive number of stem/progenitor cells in the 
ventricular zone (VZ) of the brain and regions of the cerebellum/brain stem including the 
rhombic lip (Hartfuss et al. 2001). Stem/progenitor cells in the adult mouse brain are found in 
the subventricular zone (SVZ) of the lateral ventricular wall and the subgranular zone (SGZ) 
in the dentate gyrus of the hippocampus (Alvarez-Buylla and Lim 2004). Continuous waves 
of cell proliferation and differentiation can be observed in these areas (Lim et al. 1997; Lim 
and Alvarez-Buylla 1999; Alvarez-Buylla and Lim 2004). However there are also distributed 
progenitors throughout the adult CNS which in fact outnumber the SVZ niche 
stem/progenitor cells the most important of which is the Olig2 dependant NG2+ progenitor 
cell (Ligon et al. 2006; Ligon et al. 2007; Canoll and Goldman 2008; Heinrich et al. 2014).  
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Figure 1. Neurogenesis in the adult SVZ, distributed progenitors and main cell types. Type B (NSCs), 
C (transit-amplifying progenitors), A (migrating neuroblasts) cells, NG2 stem/progenitor cells, 
Neurons, Oligodendrocytes and Astrocytes with associated markers. LV: lateral ventricle. 
1.1.2 Neurogenesis in the subventricular zone 
Subventricular zone (SVZ) neurogenesis in the adult brain has mainly been described in 
mice. The SVZ contains three important cell types; A, B and C cells (Fig. 1) (Doetsch et al. 
1997; Mirzadeh et al. 2008). The B cells are described as the neural stem cells in the SVZ, 
these slowly dividing cells give rise to the more rapidly dividing C cells, transit-amplifying 
progenitors, which in turn give rise to the type A migrating neuroblasts (Jackson and Alvarez-
Buylla 2008; Kriegstein and Alvarez-Buylla 2009). The SVZ population generates granule 
and periglomerular neurons for the olfactory bulb, it also responds to brain lesions resulting 
in the generation of astrocytes and oligodendrocytes suggesting further stem cell capabilities 
of the stem/progenitor cells from the SVZ (Romanko et al. 2004; Nait-Oumesmar et al. 
2007). The SVZ is described as a stem cell niche, this concept implies the surrounding tissues 
influence on supporting/determining the cell fate of its resident cells (Shen et al. 2008; 
Fuentealba et al. 2012; Lim and Alvarez-Buylla 2014). This influence can be related to the 
role of the tumor microenvironment, which is proposed to sustain tumor cells and fuel tumor 
progression (Hanahan and Weinberg 2011; Quail and Joyce 2013). 
1.1.2.1 The type B, C and A cells of the subventricular zone  
The radial glia are the stem cells in the ventricular zone (VZ) of the developing brain, the 
adult B cells are radial glial-like cells and believed to have a radial glial origin (Doetsch et al. 
1999; Heins et al. 2002; Merkle et al. 2004; Kriegstein and Alvarez-Buylla 2009). B cells can 
be identified by their Gfap, Pax6, Sox2, Gfapδ and Prom1 expression (Heins et al. 2002; Ellis 
et al. 2004; Roelofs et al. 2005; van den Berge et al. 2010; Codega et al. 2014). Quiescent B 
cells do not express Nestin and Egfr whereas these proteins are expressed when the B cells 
become active and re-enter the cell cycle (Codega et al. 2014; Khatri et al. 2014). The 
activation of B cells leads to the generation of Olig2+ C cells (Ligon et al. 2006; Menn et al. 
2006), which divide symmetrically approximately 3 times before transforming into Dcx+ type 
A neuroblasts that enter the rostral migratory stream (RMS) to the olfactory bulb (OB) (Fig. 
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1). Upon reaching the OB type A cells differentiate into olfactory neurons (Sawamoto et al. 
2011; Ponti et al. 2013). Although the lateral ventricular wall SVZ is described as the main 
site of neurogenesis there are also neuroblasts generated from the dorsal wall of the lateral 
ventricle (Merkle et al. 2007; Ventura and Goldman 2007).  
The SVZ has a very ordered structure where B, C and A cells are localized to specialized 
niches and there is an organized architecture to the cell relationships even within the niche 
environment. B cells extends a minute apical ending with a process situated in the ventricle 
and the cells basal process reaching into the SVZ onto blood vessels, and B cells are 
organized in a pinwheel structure together with ependymal cells (Mirzadeh et al. 2008). The 
apical process, suggested to be Prom1+, is linked to sonic hedgehog (Shh) signaling and the 
CSF circulating in the ventricles has been shown to contain the growth factor ligands Shh, 
wingless (Wnt), bone morphogenetic proteins (Bmps), retinoic acid (RA), and insulin-like 
growth factor 2 (Igf2) (Mirzadeh et al. 2008; Wong and Reiter 2008; Lehtinen et al. 2011). 
These factors are believed to control the “stemness” and proliferation of B cells. The B cells 
contact with the vasculature is also proposed to help maintain their stem cell identity with 
Betacellulin (Btc) and EGF-like growth factor secreted from endothelial cells (Gomez-Gaviro 
et al. 2012). Furthermore, B cells are influenced by neighboring ependymal cells regulating 
Bmp signaling (Gajera et al. 2010). Another example is the feed back loop from newly 
generated neurons producing gamma-aminobutyric acid (Gaba) that inhibits B cell 
proliferation (Liu et al. 2005).  
To add an extra order of complexity there is a differential region specific cell identity of the 
SVZ where NSCs from a certain region of the SVZ generate a specific type of neuron 
(Merkle et al. 2007; Merkle et al. 2013). Transplantation experiments suggest that this 
specificity is cell intrinsic and NSCs transplanted to a new region still maintain their specific 
identity. This implies that not all aspects of NSCs are determined by the SVZ stem cell 
niche/microenvironment. If this specificity is maintained in NSCs from their founding radial 
glia state it could be under epigenetic control mechanisms (Ladd-Acosta et al. 2007; 
Hirabayashi and Gotoh 2010; Lim and Alvarez-Buylla 2014). 
1.1.2.2 The embryonic ventricular zone 
Human embryonic brain, like the murine, contains a region in the ventricular wall with 
numerous radial glial and progenitor cells dividing in order to form all cells of the developing 
brain. However, the human brain has a larger neocortex, which is more cell dense compared 
to that of mice (Azevedo et al. 2009). The germinal cell layer of the embryonic brain consists 
of the VZ, inner SVZ (iSVZ) and the outer SVZ (oSVZ). The radial glia (apical radial glia) 
cells are located in the VZ with their processes reaching through the iSVZ and oSVZ out to 
the basal lamina of the brain. Both the iSVZ and oSVZ contain progenitor cells, the human 
brain needs to sustain the generation of a higher number of neural cells and is proposed to 
have a broader germinative niche. The iSVZ also contains sub apical progenitors and the 
processes of apical intermediate progenitors that have their cell soma in the VZ. Both the 
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iSVZ and oSVZ contain basal radial glia extending their processes to the basal lamina (Gotz 
and Huttner 2005; Florio and Huttner 2014).  
1.1.2.3 The adult human subventricular zone 
In the adult SVZ the differences are more apparent between mice and humans. In the adult 
human brain there is not a clear identification of the B, C and A cells and no RMS has been 
identified so far (Sanai et al. 2004; Sanai et al. 2011; Bergmann et al. 2012). While humans 
and mice both have an ependymal cell layer lining the lateral ventricles the human SVZ 
uniquely contains a structure named the astrocyte ribbon and has no clear germinal stem cell 
layer (Sanai et al. 2004; Quinones-Hinojosa et al. 2006). The astrocyte ribbon consists of 
astrocyte processes forming a structure located under the ependymal cells. The astrocyte cell 
bodies are then located further towards the striatum in a layer containing a great deal of 
vasculature. The function of this astrocyte cell layer is not yet understood and NSCs have not 
been definitively identified in this location and age. There is evidence that new neurons are 
generated in the striatum of the human brain. It is not known whether they originate from a 
certain stem cell niche, although the striatum is a structure adjacent to the SVZ (Ernst et al. 
2014).  
1.1.3 Neurogenesis in the subgranular zone of the hippocampus 
The subgranular zone (SGZ) in the dentate gyrus of the hippocampus contains a neurogenic 
niche similar to that of the SVZ. Here subgranular zone Sox2+ NSCs divide and give rise to 
progenitor cells that proliferate and mature into granule cell neurons that incorporate into the 
dentate gyrus granule cell layer (Alvarez-Buylla and Lim 2004; Piatti et al. 2006). Sox2+ 
NSCs can both reside in the SGZ as Gfap+/Nestin+ radial-like and non-radial cells (Suh et al. 
2007). They too originate from the radial glial cells in the VZ of the developing brain. 
However, SGZ NSCs predominately generate granular neurons and evidence from mouse 
models does not point to a large extent of glial cells being generated by Sox2+ NSCs but they 
would appear to be able to generate astrocytes and oligodendrocytes in vivo (Suh et al. 2007; 
Jessberger et al. 2008). This selective differentiation is proposed as an effect of the SGZ 
niche promoting the formation of new neurons rather than glia. Upon exercise induced SGZ 
neurogenesis the pool of Sox2+ NSCs will proliferate and differentiate in a type of steady 
state with the end result being a constant number of Sox2+ NSCs but additional neurons (Suh 
et al. 2007). There is evidence that neurons are generated through out adulthood in the human 
hippocampus (Spalding et al. 2013). 
1.1.4 Distributed stem/progenitor cells in the adult CNS 
A little recognized fact is that the most abundant stem/progenitor cells in mouse and human 
brain are distributed cells existing throughout all regions of the CNS parenchyma. These glial 
stem/progenitors have been described as NG2+/A2B5+/Pdgfra+/Olig2+ cells (Ligon et al. 
2006; Canoll and Goldman 2008), and found in large numbers in white and grey matter (Fig. 
1). They are believed to have the capacity to form oligodendrocytes and astrocytes in vivo. If 
isolated and cultured in vitro they can form oligodendrocytes, astrocytes and neurons (Canoll 
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and Goldman 2008), but appear to be restricted in their lineage differentiation when in vivo. 
NG2+ cells can however be reprogrammed into forming neurons in vivo by inducing Sox2 
expression following stab wound injury (Heinrich et al. 2014). 
NG2 is a chondroitin sulfate proteoglycan expressed in stem/progenitor cells of the adult 
brain. NG2+ cells have been shown to respond to mechanical injuries such as stab lesions 
(Buffo et al. 2005) and cryo-lesioning (Chen et al. 2008), as well as chemical lesions leading 
to demyelination (Islam et al. 2009). NG2+ cell responses included proliferation and the 
differentiation into astrocytes and oligodendrocytes. NG2+ cells are dependant on Olig2 
function, Olig2 is a basic helix-loop-helix transcription factor expressed in oligodendrocytes 
and stem/progenitor cells (Ligon et al. 2006). Again our knowledge regarding this is based on 
murine systems there is however evidence that a few new oligodendrocytes are generated in 
the adult human brain (Yeung et al. 2014). NG2+ cells are also abundant in human brain and 
accumulate to multiple sclerosis lesions (Chang et al. 2000). The reactive capabilities and 
sheer abundance of these cells could suggest them as likely cells of origin in gliomas.  
1.1.5 Stem/progenitor cells in the cerebellum 
The developing cerebellum has an influx of stem/progenitor cells from the VZ of the fourth 
ventricle and the rhombic lip (Hatten and Heintz 1995; Swartling et al. 2012). The wall of the 
fourth ventricle also contains radial glial cells that give rise to GABAergic progenitor cells 
and Bergmann glia (Edwards et al. 1990; Hoshino et al. 2005; Yamada et al. 2014). The 
GABAergic progenitors generate Purkinje neurons. The NSCs from the rhombic lip generate 
glutamatergic progenitors, which in turn give rise to granular progenitor cells finally 
differentiating into the granule neurons of the cerebellum (Ben-Arie et al. 1997; Fink et al. 
2006; Hevner et al. 2006). In the adult cerebellum there is no evidence of an active germinal 
cell niche neither in the SVZ of the fourth ventricle nor in the remnants of the rhombic lip. 
There are however a number of NG2+/Olig2+ cells, representing the distributed glial 
stem/progenitor cell population as seen in the rest of the brain and distributed throughout the 
white and gray matter of the cerebellum (Dawson et al. 2003; Ligon et al. 2006). 
1.2 GLIOMAS 
Glioblastoma is the most malignant grade IV variant of the general brain tumor group termed 
gliomas. Glioma is a term used for several histological subtypes of tumors with 
morphological resemblance to normal glia in the brain, the main types being astrocytic and 
oligodedroglial tumors. The astrocytic tumors include; subependymal giant cell astrocytoma 
(grade I), pilocytic astrocytoma (grade I), pilomyxoid astrocytoma (grade II), diffuse 
astrocytoma (grade II), pleomorphic xanthoastrocytoma (grade II), anaplastic astrocytoma 
(grade III) and glioblastoma (classic, giant cell glioblastoma, gliosarcoma variants) (grade 
IV). Oligodendroglial tumors consist of oligodendroglioma (grade II) and anaplastic 
oligodendroglioma (grade III).  Despite all being termed gliomas by their lineage and relation 
to glia, these tumors can not be considered as much related as different grades of tumors 
within the group of breast cancer grade I-IV and nor do they follow the same progression 
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pattern. Subependymal giant cell astrocytoma and pilocytic astrocytoma, both grade I, do 
normally not progress into higher grade tumors whereas diffuse astrocytoma (grade II) 
progresses to anaplastic astrocytoma (grade III) which subsequently can progress, but only 
rarely, to glioblastoma (termed secondary glioblastoma) (grade IV). Diffuse astrocytoma can 
also progress directly to glioblastoma (again referred to as secondary glioblastoma). 
Oligodendroglioma (grade II) progresses to anaplastic oligodendroglioma (grade III) but do 
not cross into the lineage of astrocytic tumors such as glioblastoma, although this is a 
somewhat controversial topic. Gliomas very rarely metastasize outside the brain however 
astrocytomas, oligodendrogliomas and glioblastomas are extremely infiltrative and their 
growth often ends up involving both brain hemispheres. Gliomas can display very 
heterogeneous histopathological features often shared among the different histological 
subtypes, in some cases making it impossible to visibly distinguish them from each other 
(Louis et al. 2007). However with new molecular markers as a complement to histology there 
have been several advances in glioma subclassification shedding light on the different 
biological events that are cornerstones in glioma development and progression. Here I will 
briefly describe the most common forms of gliomas based on the World Health Organization 
(WHO) 2007 Classification of Tumors of the Central Nervous System (Louis et al. 2007). 
Finally, I will provide a more in-depth review of glioblastoma, which is the main tumor type 
focused on in my thesis work. 
1.2.1 Astrocytomas 
1.2.1.1 Pilocytic astrocytoma 
Pilocytic astrocytomas (WHO grade I) are defined as relatively circumscribed, slowly 
growing, often cystic astrocytomas, representing 5-6% of all gliomas. Pilocytic astrocytomas 
are the most common glioma in children and frequently localized to the cerebellum. The 
incidence rate is 0.37 per 100 000 population per year. They occur mainly in children and 
young adults with histological features of biphasic pattern with varying proportions of 
compacted bipolar cells associated with Rosenthal fibers and loose-textured multipolar cells, 
microcysts and eosinophilic granular bodies/hyaline droplets. Although being classed as a 
grade I neoplasm that even can regress spontaneously, some pilocytic astrocytomas can lead 
to medically challenging clinical symptoms including a wide spectrum of neurological 
deficits and may eventually be fatal if located in the hypothalamus or the brain stem. 
Pilocytic astrocytomas rarely progress to more malignant forms, but when this happens they 
often have features of glioblastoma and are referred to as anaplastic pilocytic astrocytoma 
(Louis et al. 2007). Pilocytic astrocytomas can be histologically very hard to distinguish from 
reactive gliosis (a non-neoplastic proliferation/reactive change in glial cells) and diffuse 
astrocytoma, but pilocytic astrocytomas often carry a fusion gene involving the kinase BRAF 
and relatively unknown gene KIAA1549, which serves to distinguish them from alternative 
histopathologic diagnoses (Jones et al. 2008).   
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1.2.1.2 Diffuse astrocytoma 
Diffuse astrocytomas (WHO grade II) are diffusely infiltrating tumors typically affecting 
young adults, characterized by a high degree of cellular differentiation and slow growth. They 
have an incidence of 0.14 per 100 000 population per year. Diffuse astrocytomas are often 
located supratentorially and may follow a malignant progression to anaplastic astrocytoma 
followed by glioblastoma, or can directly progress to glioblastoma (termed secondary 
glioblastoma). Diffuse astrocytomas represent approximately 10-15% of astrocytic brain 
tumors and most commonly arise in the frontal and temporal lobes. Composed of well-
differentiated fibrillary or gemistocytic neoplastic astrocytes with an often microcystic 
stroma. Diffuse astrocytomas display an increased cellularity compared to normal brain but 
there is little evidence of cell proliferation, mitotic activity assessed by Ki67/MIB-1 is less 
than 5%. Occasional nuclear atypia is common but tumor cells can be hard to distinguish 
from reactive astrocytes (Louis et al. 2007). Diffuse astrocytomas are characterized by 
several genetic hallmarks; TP53 mutation has since long been associated with the disease, 
IDH1 mutation (Yan et al. 2009), and ATRX mutation have in more recent years been found 
to be characteristic for the diagnose (Kannan et al. 2012; Liu et al. 2012). Diffuse 
astrocytomas have also been associated with the DNA methylation phenotype glioma-CpG 
island methylator phenotype (G-CIMP), which in turn can be associated with MGMT 
promoter methylation (Noushmehr et al. 2010). MGMT is a DNA methyltransferase, which 
conveys temozolomide (TMZ) resistance. Silencing of this gene via promoter methylation is 
a proposed marker predicting TMZ treatment response in gliomas (Hegi et al. 2005). 
1.2.1.3 Anaplastic astrocytoma 
Anaplastic astrocytomas (WHO grade III) can arise from diffuse astrocytomas (grade II) or 
arise de novo (without prior evidence of disease). They are generally found in adults as 
opposed to young adults as in the case of diffuse astrocytomas. The incidence is 0.35 per 100 
000 population per year (Smoll and Hamilton 2014). As suggested the diffuse and anaplastic 
astrocytomas have many features in common. The histopathology is to a high extent similar 
with anaplastic astrocytomas being distinguished by their increase in cellularity, nuclear 
atypia and mitotic activity (Ki67/MIB-1 index 5-10%). There is higher variation in nuclear 
size, shape, coarsening, chromatin dispersion and increase in the prominence and number of 
nucleoli (Louis et al. 2007). The genetic alterations seen in anaplastic astrocytomas are 
largely similar to those found in diffuse astrocytomas, including TP53, IDH1 and ATRX 
mutations accompanied by G-CIMP, but with the addition of loss of heterozygosity (LOH) 
and mutations affecting PTEN (Louis et al. 2007; Yan et al. 2009; Noushmehr et al. 2010; 
Kannan et al. 2012; Liu et al. 2012). Anaplastic astrocytomas subsequently develop into 
secondary glioblastomas usually within a 2-year period (Louis et al. 2007).  
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1.2.2 Oligodendrogliomas 
1.2.2.1 Oligodendroglioma 
Oligodendrogliomas (WHO grade II) are diffusely infiltrating well-differentiated tumors, 
typically located to the cerebral hemispheres most often affecting adults, representing 5-6% 
of gliomas. They have an incidence of 0.27-0.35 per 100 000 population per year. As the 
name suggests oligodendrogliomas are characterized by round cells with a uniform round 
nucleus and clear cytoplasm resembling oligodendrocytes accompanied by a moderate 
cellularity with a “honeycomb” appearance of the tumor area. Cell proliferation is low 
usually below 5% but there is typically a dense network of thin-walled branching capillaries 
and a presence of microcalcifications (Louis et al. 2007). Oligodendrogliomas can be 
confused with reactive and other neoplastic lesions but oligodendrogliomas carry their own 
characteristic genetic hallmarks. IDH1 mutation is a required feature (Yan et al. 2009), just as 
in astrocytomas, however oligodendrogliomas do not normally carry mutations in TP53 and 
ATRX (Cryan et al. 2014), but rather are defined by a co-deletion of chromosome arms 1p and 
19q (1p/19q deletion) which results from a whole arm translocation event involving these 
same chromosomes. Oligodendrogliomas can progress to anaplastic oligodendrogliomas 
although this seems to occur somewhat slower than the progression from diffuse to anaplastic 
astrocytoma (Louis et al. 2007). 
1.2.2.2 Anaplastic oligodendroglioma 
Anaplastic oligodendrogliomas (WHO grade III) are similar to oligodendrogliomas, they 
occur slightly later in life (7-8 years) but share histological and genetic features with the 
latter. The annual incidence is around 0.07-0.18 per 100 000 population. Anaplastic 
oligodendrogliomas can develop from a lower malignant lesion or de novo. Tumors show a 
marked nuclear atypia and brisk mitotic activity, microvascular proliferation and a high 
cellularity accompanied by necrosis. Distinguished from glioblastoma by the occurrence of 
microcalcifications, a branching capillary network and the characteristic oligodendroglial 
tumor cells with a rounded hyperchromatic nucleus, perinuclear halo and few cellular 
processes (Louis et al. 2007). Anaplastic oligodendrogliomas are not believed to readily 
progress to glioblastomas, but it has been reported (Hiniker et al. 2012), and they have a 
better prognosis than anaplastic astrocytomas. Key genetic features include IDH1 mutation 
and 1p/19q deletion as observed in oligodendrogliomas (Louis et al. 2007; Yan et al. 2009). 
In addition anaplastic oligodendrogliomas can show amplifications of EGFR, PDGFRA, 
MYC, MYCN, CDK4, MDM2, MDM4 and deletions/mutations of CDKN2A/B, CDKN2C, 
PTEN, RB1 which would explain the malignant progression, however these events are not as 
common as they are in glioblastomas (Louis et al. 2007). 
1.2.3 Glioblastoma 
Glioblastoma (WHO grade IV) is the most aggressive and frequent brain tumor in adults. 
Most commonly it is a primary tumor arising de novo with peak age of incidence between 45 
and 75 years of age (mean age 61.3). The incidence is 3-4 per 100 000 population per year. 
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Glioblastomas are characterized by nuclear atypia, cellular pleomorphism, mitotic activity, 
vascular thrombosis, microvascular proliferation and necrosis. They account for 12-15% of 
all intracranial neoplasms and 60-75% of astrocytic tumors. They are most often localized in 
the subcortical white matter of the cerebral hemispheres with combined fronto-temporal lobe 
location being the most common. However glioblastoma cells migrate along white matter 
tracts, much as developing progenitor cells in the brain do, into regions such as the corpus 
callosum and along vasculature often resulting in the tumor engaging large regions of the 
brain expanding into multiple lobes and the contra lateral hemisphere. The clinical history is 
often as short as three months when the tumor arise de novo, referred to as primary 
glioblastoma. Glioblastomas can also develop from diffuse and anaplastic astrocytomas and 
are then referred to as secondary glioblastoma (<10% of all glioblastomas). While 
glioblastomas often share several histopathological features with diffuse and anaplastic 
astrocytomas, hence they are grouped together as astrocytic tumors (Louis et al. 2007). This 
is most likely a misleading view of glioblastomas, since they display a very wide array of 
additional histological and molecular features. Current research dictates that primary and 
secondary glioblastomas should be regarded as two different diseases (Parsons et al. 2008; 
Brennan et al. 2013). Prominent microvascular proliferation and/or necrosis are essential for 
the diagnose, this is often accompanied by heterogeneous features ranging from epithelial 
structures to poorly differentiated cells. Epithelial like structures are referred to as adenoid, 
containing cells with large oval nuclei, prominent nucleoli and round well-defined cytoplasm 
forming glandular structures. Several cellular compositions can be observed in glioblastomas 
e.g. with small elongated cells densely packed with hyperchromatic nucleoli, modest atypia, 
low level of GFAP but high proliferative activity (small cell glioblastoma). Like 
oligodendroglioma glioblastomas can contain cells reminiscent of oligodendroglial cells. 
Giant cell glioblastomas contain a predominant fraction of large multinucleated cells, which 
are also a common feature of glioblastomas but then not the dominating cell type. 
Gemistocytes found in diffuse and anaplastic astrocytomas are also often found in 
glioblastomas. Other cell features include granular cells and lipidized cells. Perhaps the most 
extreme histological features are those found in gliosarcomas with a mixture of gliomatous 
and sarcomatous tumor tissues sometimes even containing tumor cells with mesenchymal 
differentiation such as the formation of cartilage, bone and muscle (Louis et al. 2007).    
For decades, glioblastoma patients have been managed with a combination of neurosurgery, 
standard-of-care chemotherapy/radiotherapy and with additional experimental therapies; 
however, the disease is incurable and patient survival remains dismal at a median of 12-15 
months (Stupp et al. 2005; Van Meir et al. 2010). Enumerable studies have been published 
correlating histologic subclasses with clinical outcomes in attempts to provide meaningful 
prognostic indicators.  Unfortunately, these studies were usually in conflict with each other as 
in the case of giant cell glioblastoma where some data suggested a worse prognosis while 
others highlighted a better clinical outcome attributed to a less infiltrative tumor growth 
pattern (Huang et al. 1996; Louis et al. 2007). Similarly, limited studies on gliosarcomas have 
hinted at a more favorable prognosis but later larger clinical trials failed to demonstrate such 
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a benefit (Meis et al. 1991; Galanis et al. 1998; Han et al. 2010).  Presently, histological 
subtypes of glioblastoma are clinically treated the same and outcomes remain poor across all 
categories. 
1.2.3.1 Genetic alterations in Glioblastoma 
Glioblastomas, like other types of cancer, carry a diverse set of genetic alterations in 
oncogenes and tumor suppressor genes. Glioblastoma is associated with a characteristic set of 
genomic alterations including EGFR amplification, EGFRvIII deletion, chr7 gain, 
CDKN2A/B deletion, LOH of chr10, PTEN LOH/deletion/mutation, CDK4 amplification, 
PDGFRA amplification/mutation, MDM2 amplification, MDM4 amplification, MET 
amplification, CDK6 amplification, PIK3CA/PIK3R1 mutations, NF1 mutation/deletion, RB1 
mutation/deletion and TP53 mutation/deletion. The end results of these genetic events are; 
88-90% of cases with altered RTK/RAS/PI3K signaling leading to AKT and/or MAPK 
pathway activation, 86-87% of cases with altered p53 activation/signaling impairing normal 
p53 response, 78-79% of cases with altered RB signaling uncoupling normal cell cycle 
control and restriction (TCGA 2008; Brennan et al. 2013).  
There is also a subset of de novo glioblastomas with IDH1 mutations however it is likely that 
these tumors represent secondary glioblastoma despite the lack of a previous low-grade tumor 
detected in the patients (Parsons et al. 2008; Yan et al. 2009). These tumors, just like 
secondary glioblastomas, which also carry IDH1 mutations, show a higher frequency of TP53 
and ATRX mutations as well as displaying the IDH1 mutation induced glioma-CpG island 
methylator phenotype (G-CIMP) all of which are more related to astrocytomas than to 
primary glioblastoma (Noushmehr et al. 2010; Kannan et al. 2012; Liu et al. 2012; Brennan et 
al. 2013). As low grade gliomas progress there is an accumulation of genetic events found in 
glioblastomas; RB1 mutation/loss, CDKN2A loss and CDK4/6 amplifications seem to be 
related with the early stages of progression whereas PTEN loss, PDGFRA amplification and 
EGFR amplification are proposed to finally transform the lower grade lesion into a 
glioblastoma (Louis et al. 2007). 
Glioblastomas display great inter and intra tumor heterogeneity also at the genetic level. 
Single tumors have been observed to contain different cell clones with unique genetic events 
such as EGFR, PDGFRA and MET amplifications. This heterogeneity is likely to pose 
problems for treatments, with different cell populations possibly relying on different cell 
signaling pathways (Snuderl et al. 2011). The evolution of different tumor cell clones could 
imply a functional relationship between them, possibly a dependence on each other, opening 
the door for developing treatments targeting tumor cell-to-tumor cell interactions.   
Despite that glioblastomas have a well defined genomic landscape with EGFR, PDGFRA, 
CDKN2A, PTEN, TP53, RB1 and NF1 aberrations described relatively long ago new genetic 
events such as IDH1, ATRX mutations and now more recently the mutations of the hTERT 
promoter and loss of QKI are still being added (Louis et al. 2007; Parsons et al. 2008; 
Brennan et al. 2013). Continuous efforts and more knowledge are bound to further identify 
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genetic events important in gliomagenesis. This fact points to the need for molecular based 
subclassifications and further molecular based functional analysis of glioblastomas. 
1.2.3.2 Molecular subclasses of glioblastoma 
An updated approach to the molecular subclassification of glioblastoma was presented by the 
seminal works of TCGA Research Network, which among other things, highlighted four 
novel molecular subclasses based on gene expression in a large cohort of glioblastoma tissue 
samples (TCGA 2008; Verhaak et al. 2010; Brennan et al. 2013).  These studies showed that 
molecular subclasses could be associated with different neural cell types and cancer pathways 
as well as differential response to more or less aggressive clinical therapies.  Interestingly, 
similar glioma subclasses were first described as a progression model, although this study 
combined anaplastic astrocytomas (grade III) and glioblastomas (Phillips et al. 2006). This 
progression model has not been proven valid for the TCGA subclasses based on de novo 
glioblastomas. 
TCGA showed by mRNA expression profiling that glioblastomas could be grouped into four 
molecular subclasses, namely: Classical, Proneural, Neural and Mesenchymal (not correlated 
with WHO histological subtypes). The subclasses are linked to different gene expression 
signatures with Neural being more close to normal brain and astrocytes, Classical and 
Proneural more represented by proliferation and neural progenitor markers. Proneural 
correlated more with oligodendrocytes than astrocytes whereas the opposite was true for 
Classical, Mesenchymal includes high expression of both mesenchymal and inflammatory 
cell markers and resembles cultured astroglia (Verhaak et al. 2010). Given that non-tumor 
cell gene signatures influence these subclasses, the signatures in part reflect the 
contaminating presence of normal neural and glial cells, necrosis, vascular proliferation, 
inflammatory cells and other non-tumor cell types. There are some genetic correlations to the 
mRNA expression subclasses, IDH1 and ATRX mutated tumors fall within the Proneural 
subclass, IDH1 mutations also go hand in hand with G-CIMP. Regarding other genetic 
alterations, such as EGFR and PDGFRA amplifications proposed to be linked to Classical 
versus Proneural subclasses and RB1/NF1 alterations in the Mesenchymal subclass, the 
correlations are not always as strong (Fig. 2) (TCGA 2008; Verhaak et al. 2010; Brennan et 
al. 2013). When molecular subclasses were correlated with patient survival in response to 
more or less intensive therapeutic strategies, differences in survival were noted suggesting but 
not strongly supporting a biologic relevance to these subclasses. The Classical subclass had 
greatest benefit of aggressive treatment whereas there was none in the Proneural (Verhaak et 
al. 2010). In the TCGA follow-up study it is shown that G-CIMP/IDH1 mutation are related 
to and predominantly explain the survival advantage noted in the Proneural subclass. 
Interesting in regard to the previous report concerning the benefit of aggressive treatment in 
the Classical subclass, MGMT promoter methylation was found to be a predictive biomarker 
in the Classical subclass but not in others (Brennan et al. 2013).  
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Figure 2. TCGA gene expression subclasses Proneural, Neural, Classical and Mesenchymal. IDH1 
mutated tumors have here been given their separate class. Common includes frequently altered genes. 
Right panel includes genes with upregulated mRNA highlighted for each expression subclass 
*mutated, amp: amplified, del: deleted, loh: loss of heterozygosity. 
As these studies were based entirely on tissue samples, some limitations include genomic 
contribution of non-tumor components such as inflammatory cells, blood vessels, microglia 
as well as non-neoplastic brain constituents like astrocytes, oligodendrocytes and neurons 
(TCGA 2008; Verhaak et al. 2010). The initial TCGA study defining the expression 
subclasses did reconfirm the presence of the Proneural, Classical and Mesenchymal 
subclasses in a small cohort of xenografts (Verhaak et al. 2010), however there could still be 
issues with non-tumor cell contaminations in such a setting. Importantly, given the intra 
tumor heterogeneity of glioblastoma it is unknown how well the region selected for analysis 
will represents the rest of the tumor (Snuderl et al. 2011; Patel et al. 2014).  
Nonetheless the emergence of these mRNA expression based subclasses has helped to drive 
research in the field, especially in regards to correlation of glioblastoma genomics with 
mRNA expression patterns. The most recent attempt in the TCGA work has been to add a 
new large scale proteomic screen to evaluate activated pathways in the different glioblastoma 
subgroups (Brennan et al. 2013). MAPK pathway activation showed some increase in the 
Mesenchymal subclass whereas the PI3K pathway was more active in the Proneural and both 
groups had mTOR pathway activation. The initial results pointed to a very complex and non-
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linear relation between expression subclasses, genetic profiles and protein levels, however the 
addition of protein analysis will surely help to establish more biologically relevant 
glioblastoma subgroups and identify drug targets in future studies. 
1.2.3.3 Cancer stem cells in glioblastoma 
Glioblastoma cancer stem cells (CSCs) are the population of cells with the potency to form 
neurospheres, when cultured under NSC conditions, showing multi lineage (neuronal-, 
astrocytic- and oligodendroglial-like) differentiation in vitro. To be considered true CSCs 
they should form tumors, recapitulating the founding tumor, when injected into the brains of 
immunodeficient NOD/SCID mice (Singh et al. 2003; Singh et al. 2004). 
Even though the term CSCs has been accepted for variants of leukemia there is still a debate 
regarding CSCs in solid tumors. Stem cells, whether it comes to cancer or normal stem cells, 
are functionally defined as cells with the capacity of self-renewal and multipotency. There are 
two scenarios for the generation of these CSCs; The first being mutation of cells that already 
have reached their differentiated and mature state, causing dedifferentiation leading to the 
generation of cancer cells with stem cell attributes. A second possibility is the initial mutation 
taking place in stem cells generating cancer cells that already possess the attributes of self-
renewal and multipotency (Singh et al. 2004). Stem cells continuously self-renew throughout 
our life span and would thereby be more likely to accumulate mutations. Even if the origin of 
CSCs is not defined, cancer cells with stem cell properties are clearly found in various types 
of cancers including glioblastoma (Lapidot et al. 1994; Al-Hajj et al. 2003; Singh et al. 2003; 
Singh et al. 2004). 
An ongoing challenge with glioblastoma CSCs has been to identify a robust defining 
biomarker that can be used for prospective isolation and study of such cells. Initial studies of 
the surface marker PROM1 (CD133/AC133/Prominin-1) suggested that PROM1+ cells were 
responsible for repopulating tumors while PROM1- cells did not have this capacity (Singh et 
al. 2003; Singh et al. 2004).  In time, this however proved to be less reliable as subsequent 
studies showed that both PROM1+ and PROM1- populations were able to generate tumors 
following transplantation into mice (Beier et al. 2007; Shmelkov et al. 2008). This has also 
been the case for other markers described in the literature. Despite the absence of a single 
defining biomarker, there is high expression of a large number of stem cell associated genes, 
e.g. NESTIN, GFAP, SOX2, A2B5, NANOG, OKT4, CD44 and KLF4 in glioblastomas 
(Ben-Porath et al. 2008; Ogden et al. 2008; Anido et al. 2010; Holmberg et al. 2011; Elsir et 
al. 2013). Several of these are transcription factors linked to embryonic development and 
stem/progenitor cells suggesting an activity of stem/progenitor cell associated transcriptional 
networks in glioblastoma. Genetically engineered mouse models (GEMMs) have also 
provided extra support to CSCs residing in the tumors giving rise to transient amplifying cells 
and differentiated progeny in a fashion similar to NSCs (Alcantara Llaguno et al. 2009). It 
remains unclear how locked the glioblastoma cells are to their specific stem cell state and 
other possible states along the differentiation pathway such as progenitor and terminally 
differentiated cell states. To add more complexity to the stem cell markers new research has 
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shown that many are context dependent acting together with other factors to exert their final 
function e.g. GFAP is expressed in stem cells as well as in differentiated astrocytes 
potentially serving different functions (Codega et al. 2014).  
The CSC theory has been proposed as an alternative to the clonal evolution theory in cancer 
(Nowell 1976), where instead of there being the dominance of advantageous clones that 
prevail there is a small percentage of CSCs sustaining tumor growth. The two theories are 
also combined where CSCs and clonal evolution are both contributing biologic forces, which 
together with the tumor microenvironment and interclonal cooperativity give rise to these 
heterogeneous tumors (Hanahan and Weinberg 2011; Valent et al. 2012). 
1.2.3.4 Glioblastoma cell of origin 
The glioblastoma cell of origin has long been debated. Theories about and identification of 
CSCs in glioblastoma have certainly refueled this question. Reviewing the literature in 
regards to glioma models and especially GEMMs it is more likely that glioblastomas arise 
from transformed neural stem/progenitor cells than from differentiated neural cells. GEMMs 
utilizing stem/progenitor associated genes such as Gfap and Nestin for cell targeting illustrate 
that cells expressing these genes can be transformed into glioblastomas (Uhrbom et al. 2005; 
Hede et al. 2009; Chow et al. 2011). This transformation process more readily occurs in stem 
cell niches of the adult brain, such as the SVZ and can be induced by a number of 
glioblastoma associated genetic events (Swartling et al. 2012). Mouse glioma cells have also 
been shown to be dependent on Olig2 function similar to normal oligodendrocyte lineage 
cells and raising the possibility that glioblastoma arise from this lineage (Ligon et al. 2007; 
Mehta et al. 2011). In addition to niche progenitors the fact that NG2+/Olig2+ progenitor cells 
are the most abundant dividing cells in the brain suggest that these may be source of 
glioblastoma. Even though GEMMs are not as prone to form glioblastomas when 
differentiated cells are targeted under more physiological conditions, it is possible to 
transform neurons into glioblastoma cells (Friedmann-Morvinski et al. 2012).  
1.2.3.5 DNA and histone modifications in glioblastoma 
Epigenetics has had a popularity boom in cancer research during recent years. Epigenetics is 
a concept describing non-genetic changes resulting in gene regulation that is inherited by 
daughter cells. Basically what is referred to when using the word epigenetics is DNA and 
histone modifications such as methylation and acetylation. Stem, progenitor and 
differentiated cells will hold different epigenetic status resulting in specific gene regulation 
affecting cell identity and ultimately cell function (Hirabayashi and Gotoh 2010). Exactly 
how this works is not yet fully mapped and understood. In cancer there is a growing body of 
evidence that DNA/histone modifications and proteins involved in these processes are 
relevant to the disease (Jones and Baylin 2007; Nagarajan and Costello 2009). 
DNA methylation occurs throughout the genome, it is believed that the methylation in and 
before promoter regions plays the largest role in gene regulation. Methylation takes place in 
CpG domains around gene promoters and enhancers (McClelland and Ivarie 1982). A 
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methylated promoter subsequently often results in a silenced gene and this has been shown 
for p16/CDKN2, RB1 and PTEN in gliomas (Costello et al. 1996; Nakamura et al. 2001; 
Baeza et al. 2003). There is a growing interest in the DNA methylation patterns of cancer and 
it is becoming clear that the methylation patterns in the cancer genome are much more 
complex than first thought and not only confined to promoter regions (Eckhardt et al. 2006). 
The latest work from TCGA includes the methylation status of a number of glioblastomas 
and investigates possible correlations between methylation status and molecular subclass 
(Brennan et al. 2013). DNA methylation, gene expression subclass and genetic events are 
however not shown to correlate except when it comes to the IDH1 mutated tumors showing 
G-CIMP which is also the case for low grade gliomas with IDH1 mutation (Noushmehr et al. 
2010; Brennan et al. 2013). IDH1 mutation has been suggested to affect the general DNA 
methylation status of the cancer cell (Sasaki et al. 2012). Another example is loss of DNA 
(cytosine-5-)-metyltransferase (DNMT), an enzyme that normally establishes methylated 
cytosine residues. Loss of DNMT function leads to the hypomethylation of the cancer cell 
genome and deregulated gene expression together with increased genomic instability (Eden et 
al. 2003). 
Histone modifications are fundamentally able to influence gene expression. The nucleosome, 
approximately 146 bp of DNA wrapped approximately twice around an octamer of the four 
core histone proteins (H2A, H2B, H3, H4) is the basic subunit of chromatin (Luger et al. 
1997). Methylation and acetylation are the most described histone modifications (Turner 
2005), this will together with certain proteins such as heterochromatin protein HP1 and linker 
histone H1 regulate if the chromatin is configured as euchromatin or heterochromatin and 
thereby controlling gene transcription (Nielsen et al. 2001). The most studied and perhaps the 
most important histone modifications are methylations of H3K9, with the addition of two 
methyl groups H3K9me2 being the first more reversible step of gene silencing and the 
subsequent addition of yet another methyl group, giving three in total, that is H3K9me3 
representing fully silenced DNA and heterochromatin compaction (Tachibana et al. 2001). 
Histone methylation of H3K27 has also been linked to gene repression whereas methylation 
of H3K4, K36 and K79 has together with acetylation of histones been implicated in 
transcriptional activation (Clarke et al. 1999; Nakamura et al. 2002; Krogan et al. 2003; 
Krogan et al. 2003). There are histone modifiers deregulated and mutated in glioblastoma like 
histone deacetylases (HDACs) (Lucio-Eterovic et al. 2008; Parsons et al. 2008), there are 
mutations targeting the histones themselves e.g. H3.3 (Schwartzentruber et al. 2012), 
although found in pediatric gliomas not in adult glioblastomas (Brennan et al. 2013), and 
there are amplifications and deletions in genes regulating H3K9 methylation in 
medulloblastoma (Northcott et al. 2009).  
1.2.3.6 Glioblastoma patient derived cell lines 
The methodology for establishing PDCLs from patient tissue was first pioneered through 
CSC studies in glioblastoma. Cultures enriched for CSCs were created by culturing 
glioblastoma cells in NSC conditions (Singh et al. 2003; Galli et al. 2004; Singh et al. 2004). 
  17 
Glioblastoma cells are grown in serum free media supplemented with recombinant human 
(rh) EGF and rh bFGF on non-adherent plates like NSCs. Glioblastoma cells can then as 
NSCs form neurospheres (or rather tumorspheres). This is in contrast to cultures utilizing 
serum containing media and adherent plates that induce differentiation in NSCs. Historical 
glioblastoma cell lines grown in serum, e.g. U87MG, grown in culture for many years lack 
genomic and mRNA expression profiles that are similar to patient samples and do not 
recapitulate the histopathology as xenografts (Sakariassen et al. 2006; Li et al. 2008; Hodgson 
et al. 2009). In contrast, glioblastoma cells grown under NSC conditions (PDCLs/CSCs) have 
been shown to faithfully recapitulate morphologic and immunophenotypic profiles of their 
tumors of origin both in vitro and in vivo (Galli et al. 2004; Lee et al. 2006; Wakimoto et al. 
2011). However the extent and degree to which large number of cell lines may exhibit this 
fidelity has not been extensively tested. 
Hence, stem cell conditions are proposed to maintain the stem/progenitor cell phenotype, 
whereas serum cultured lines are suggested to undergo a form of differentiation leading to the 
generation of lines with a more “clonal/restricted” cell phenotype (Singh et al. 2003; Singh et 
al. 2004; Lee et al. 2006; Pfenninger et al. 2007; Li et al. 2008; Hodgson et al. 2009). 
Glioblastoma cell lines cultured in NSC conditions are after a few number of passages devoid 
of non-tumor cell contamination. Thus, they represent the ideal model to identify true cancer 
cell intrinsic characteristics of glioblastoma.  
1.3 MEDULLOBLASTOMA 
Although not a glioma this is a grade IV brain tumor worth mentioning in the context of this 
thesis. Medulloblastomas are malignant invasive embryonal tumors of the cerebellum. They 
arise mainly in children but also occur in teenagers/young adults with an incidence of 0.5 per 
100 000 children less than 15 years per year. There are several histological subgroups of 
medulloblastoma; Desmoplastic/Nodular medulloblastoma, Medulloblastoma with extensive 
nodularity, Anaplastic and Large cell medulloblastoma. Medulloblastomas have their own 
genetic characteristics separating them from astrocytomas, oligodendrogliomas and 
glioblastomas with MYC being one of the most common amplifications associated with large 
cell medulloblastoma and poor clinical outcome. Sonic hedgehog (SHH) signaling is also 
strongly associated with medulloblastomas of the desmoplastic variant most commonly 
exhibiting loss of PTCHD which is an inhibitor of the SHH pathway. There are also 
similarities between medulloblastomas and gliomas such as; CDK6 gain and deletions of 
PTEN and CDKN2A (Louis et al. 2007). There are four molecular subclasses of 
medulloblastoma; WNT, SHH, Group 3 and Group 4 associated with activation of different 
pathways and patient demographics (Cho et al. 2010; Northcott et al. 2010). 
Medulloblastomas of the WNT subclass arise outside the cerebellum from cells of the dorsal 
brain stem whereas SHH subtype tumors arise from within the cerebellum (Gibson et al. 
2010). SHH tumors have been proposed to originate from the granular neuron precursor cells 
(GNPCs) (Schuller et al. 2008). PROM1 expression and its association to CSCs is another 
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feature shared between medulloblastomas and glioblastomas (Singh et al. 2003; Singh et al. 
2004; Raso et al. 2011). 
1.4 PROMININ-1 (PROM1/CD133) 
Prominin-1 was the first 5-transmembrane (5-TM) protein identified in the prominin family 
(Miraglia et al. 1997; Mizrak et al. 2008).  Since its discovery Prominin-1 has been described 
by several research groups as a stem cell marker although the amount of evidence for this in 
the normal nervous system has been very limited and surpassed by the interest in the cancer 
stem cell community (Bauer et al. 2008). PROM1 is a single-chain polypeptide of 865 amino 
acids with 5-TM regions, extracellular N-terminus and cytoplasmic C-terminus and two 
extracellular loops with eight sites each for N-linked glycosylation (Miraglia et al. 1997). 
PROM1 was first discovered in human hematopoietic progenitor cells but later also described 
in mouse tissue (Miraglia et al. 1997; Weigmann et al. 1997). Mouse Prom1 has only a 60% 
amino acid identity with the human PROM1 but on the other hand has a very similar protein 
structure; 5-TM, 858 amino acids, extracellular N-terminus, cytoplasmic C-terminus, two 
extracellular loops with eight N-glycosylation sites (Weigmann et al. 1997). Prominin-1 has 
been detected in many different tissue types; brain, intestine, kidney, bone marrow, heart, 
liver, lung, pancreas, placenta, skeletal muscle, and testis either through mRNA or antibody 
(Corbeil et al. 2001). At least two splice variants exist for human PROM1 and as many as 8 
splice forms have been described for mouse Prom1 (Fargeas et al. 2004). Prominin-1 can 
often be seen in association with plasma membrane protrusions such as microvilli, in rod 
photoreceptor cells invaginations and myelin sheaths (Maw et al. 2000; Yang et al. 2008; 
Corbeil et al. 2009). Evidence suggests that Prominin-1 interacts with microdomains known 
as lipid rafts in the plasma membrane (Corbeil et al. 2001). Mutations in PROM1 are believed 
to cause retinal degeneration (Maw et al. 2000). 
PROM1 has been associated with CSCs in a wide number of cancers but particularly in the 
CNS (Lapidot et al. 1994; Al-Hajj et al. 2003; Fargeas et al. 2004; Singh et al. 2004; Ding et 
al. 2013). Even though researchers have shown great interest in studying Prominin-1 there is 
limited knowledge about the proteins actual function and its expression across the 
differentiation spectrum of cells. 
1.4.1 Prominin-1 in embryonic CNS development 
Prominin-1 expression was initially reported in the VZ, retina and spinal cord of the 
developing CNS (Corbeil et al. 2000; Uchida et al. 2000; Corbeil et al. 2009) although the 
evidence for its expression in normal and well defined stem cells in vivo has been limited by 
difficulty in detecting the protein. PROM1+ cells isolated from the human fetal ventricular 
zone have the ability to generate neurospheres, which retain self-renewal and multi-lineage 
differentiation capacity (Uchida et al. 2000). During mouse embryonic brain development 
splice variant 1 (s1) is the dominant form of Prom1 (Corbeil et al. 2009). Previous reports 
suggested that Prom1+ cells isolated from the perinatal (P7) mouse cerebellum were 
multipotent neural stem cells (Lee et al. 2005). However each of these methods did not 
  19 
specifically isolate the Prom1+ cells and were likely containing other progenitor cells from 
the SVZ/other regions, which readily generate neurospheres, calling into question the actual 
potential of Prom1+ cells in vivo.  
1.4.2 Prominin-1 in the adult CNS 
In the adult brain, Prominin-1 expression has been reported in ependymal cells and murine 
hippocampus (Coskun et al. 2008; Walker et al. 2013). In transgenic Prom1-LacZ mice, 
Prom1/LacZ was co-expressed with Gfap in cells of the SVZ having properties of multipotent 
self-renewing neural stem cells (Coskun et al. 2008). That Prom1+  cells are stem/progenitor 
cells from the SVZ/VZ is supported by other recent studies (Codega et al. 2014; Khatri et al. 
2014). However, Prom1/LacZ+/Gfap- cells single-sorted from this region were not able to 
form secondary neurospheres or to differentiate into all neural lineages (Coskun et al. 2008). 
Prom1/LacZ expression was also noted in cells with non-stem cell phenotypes widely 
throughout the adult mouse brain regions but whether the endogenous gene is expressed in a 
similar pattern was not fully established and artifacts of transgenic expression make 
determination of this difficult (Beckervordersandforth et al. 2010; Ding et al. 2013).  In 
regards to examination of Prom1 expression in normal brain it has been identified in myelin 
sheaths and Prom1 s3 mRNA was identified in cells expressing Olig2 (Corbeil et al. 2009). 
Studies in different organ systems (e.g. retina, prostate and hematopoietic systems) have also 
highlighted the non-stem cell expression and function of Prominin-1 (Missol-Kolka et al. 
2011; Arndt et al. 2013; Gurudev et al. 2013).  
It is suggested that significant differences may exist between mouse and human Prominin-1 
(Wang et al. 2013). There are also discrepancies between the PROM1 mRNA and protein 
expression reported in human colon tissue due to differences in glycosylation affecting 
antibody specificity (Kemper et al. 2010). These are issues that should be taken into account, 
especially since diverse splice variants and differences in glycosylation have been reported to 
distinguish different cell types/cell states and are likely to reflect fundamentally diverse 
functions of Prominin-1 (Corbeil et al. 2009; Kemper et al. 2010).  
1.4.3 Prominin-1 in glioblastoma 
Prominin-1 is believed to identify tumor-initiating cancer stem cells in a wide range of cancer 
types including leukemia (Lapidot et al. 1994), breast (Al-Hajj et al. 2003) and glioblastoma 
(Singh et al. 2003). The cancer stem cell hypothesis suggests that only a minor subpopulation 
of the tumor cells maintain tumor growth and have the indefinite capacity to self-renew. 
PROM1 is ubiquitously referred to as such a marker expressed in only a minor subpopulation 
of stem cells in glioblastoma. Based on flow cytometry analysis, PROM1+ cells in 
glioblastoma have been described as tumor initiating cells able to propagate tumor growth in 
immunodeficient NOD/SCID mice xenograft models and confer radioresistance (Singh et al. 
2003; Singh et al. 2004; Bao et al. 2006; Kang and Kang 2007). However, glioblastoma 
PROM1- cells can also contribute to tumor propagation (Galli et al. 2004; Beier et al. 2007; 
Joo et al. 2008; Wang et al. 2008). This raises the possibility that Prominin-1 may not be as 
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closely linked with “stemness” or tumor initiating phenotype in normal cells or cancer cells 
as previously proposed. Recent studies of Prominin-1 have used alternatives to flow 
cytometry, which allow more direct in situ visualization of its expression. Such studies 
increasingly describe differences in expression of the multiple and complex Prominin-1 
isoforms in mouse and human. These studies have also increasingly highlighted Prominin-1 
non-stem cell functions in the hematopoietic, retinal and prostate systems (Missol-Kolka et 
al. 2011; Arndt et al. 2013; Gurudev et al. 2013). In addition, expression of Prominin-1 has 
been reported as regulated by hypoxia, supporting the possibility that Prominin-1 may be a 
dynamically regulated protein not necessarily associated with cell lineage or stem cell 
phenotypes (Griguer et al. 2008). 
Multiple studies have shown neurosphere formation or PROM1 antigen expression to be 
associated with shorter survival in patients and in mice transplanted with such tumor cells 
(Beier et al. 2007; Zeppernick et al. 2008; Laks et al. 2009). This would imply that PROM1 
could serve as a prognostic marker however the biology behind this has not been explained.  
1.5 NPM1 (NUCLEOPHOSMIN/B23) 
Cancer cells, including glioma cells, display increasing nucleolar prominence and number 
alongside coarsening and dispersion of chromatin (Louis et al. 2007). Given this the 
nucleolus and nucleolar proteins hold a potentially interesting role in cancer. NPM1 is a non-
ribosomal nucleolar protein that has been related to cancer (Grisendi et al. 2006). Npm1 
deficient mice display a defective haematopoiesis, and myelodysplastic syndrome (MDS), 
which is embryonic lethal (Grisendi et al. 2005; Grisendi et al. 2006). In addition, Npm1-/- 
embryos (E10.5) lack proper forebrain with the subdivision between metencephalon and 
mesencephalon shifted anteriorly. Analysis of neural tissues revealed marked apoptosis 
suggesting NPM1 serves a crucial function in normal brain development (Grisendi et al. 
2005). 
1.5.1 The nucleolus and nucleolar stress 
Nucleoli are dynamic nuclear compartments rich in protein and RNA where the cell’s 
ribosome biogenesis takes place (Hernandez-Verdun 2006). The nucleolus is said to mirror a 
series of metabolic changes in cancer cells and human tumors with nucleolar hypertrophy 
have worse prognosis (Derenzini et al. 2009). Of interest in relation to the recent finding 
regarding hTERT promoter mutation in glioblastoma (Brennan et al. 2013), is the fact that the 
nucleolus is the assembly place for the telomerase complex (Yang et al. 2002). Furthermore, 
TP53 mutations and RB loss, also common in glioblastoma, are related a higher degree of 
nucleolar hypertrophy (Derenzini et al. 2004; Trere et al. 2004).   
The nucleolus lacks a lipid bi-layer, and nucleoli form around ribosomal DNA (rDNA). The 
human rDNA genes are arranged in the form of tandem repeats at the chromosomal nucleolar 
organizer regions (NORs), there are around 400 copies of the rDNA gene in humans situated 
on the p-arms of the five acrocentric chromosomes 13, 14, 15, 21 and 22 (Boisvert et al. 
2007; Shaw and Brown 2011). RNA polymerase I (RNA pol I) initiates transcription and this 
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leads to the formation of the nucleolus. The nucleolus is divided into three main 
subcompartments; fibrillar center (FC), dense fibrillar component (DFC) and granular 
component (GC). rDNA transcription is thought to occur at the border between the FC and 
DFC, with RNA pol I subunits predominately in the FC (Boisvert et al. 2007). RNA pol I 
transcribes 47S precursor RNA that is subsequently processed and cleaved into the 28S, 18S 
and 5.8S ribosomal RNAs (rRNAs). Small nucleolar ribonuclear proteins (snoRNPs) help 
process the rRNA subunits in the DFC region, which are then assembled in ribosome 
subunits in the GC of the nucleolus. This process involves a number of ribosomal proteins 
and 5S rRNA (Fig. 3) (Boisvert et al. 2007).  
Nucleolar proteins are in constant flux between the nucleolus, nucleoplasm and cytoplasm 
(Lam et al. 2007). This flux of proteins has been assigned an important role in cellular stress 
signalling. The nucleolus responds to cellular stress that results in disturbances/defects in 
ribosome biogenesis (Olson 2004; Mayer and Grummt 2005; Boulon et al. 2010). This may 
be induced by mutated ribosomal/nucleolar proteins, a variety of chemotherapeutic drugs, 
irradiation, viral infection and heat shock (Draptchinskaia et al. 1999; Rubbi and Milner 
2003; Burger et al. 2010). This is referred to as “nucleolar stress” or “ribosomal stress” (Fig. 
3) (Zhang and Lu 2009). Nucleolar stress can lead to p53 activation resulting in cell cycle 
arrest, apoptosis, differentiation or senescence (Lindstrom and Zhang 2008; Drygin et al. 
2009; Drygin et al. 2010; Morgado-Palacin et al. 2012). However there are p53 independent 
mechanisms also resulting in cell cycle arrest. Following nucleolar stress RPL11 is released 
from the nucleolus, RPL11 can destabilize E2F-1 and PIM1 kinase as well as inhibiting the 
expression of c-Myc and 5S RNA (Dai et al. 2007; Dai et al. 2010; Iadevaia et al. 2010; 
Donati et al. 2011). There are still plenty of additional proteins possibly associated with the 
nucleolus that have not yet been characterized but could play additional roles in nucleolar 
stress (Wool 1996; Lindstrom 2009; Warner and McIntosh 2009).  
The nucleolus has also been assigned a role in organizing chromosome domains in the 
nucleus. Essentially, the nucleolus could be involved in the epigenetic and genetic regulation 




Figure 3. The nucleolus in the normal cell (left). rDNA transcription, rRNA processing and ribosome 
subunit assembly. NPM1 is located mainly in the GC acting as a chaperone. During nucleolar stress 
(right) NPM1 becomes dispersed from the nucleolus into the nucleoplasm where it inhibits MDM2 
and stabilizes p53 and ARF. FC: fibrillar component, DFC: dense fibrillar component GC: granular 
component. 
1.5.2 NPM1, a stress sensing nucleolar chaperone 
NPM1 is a very abundant 37kDa phosphoprotein mainly localized in the nucleolus, more 
concentrated to the GC (Fig. 3). It takes part in the ribosome biogenesis and can shuttle 
between the nucleus and cytoplasm transporting pre-ribosomal particles (Grisendi et al. 
2006). NPM1 may act as a histone chaperone given that it binds histones and assembles 
nucleosomes in vitro (Okuwaki et al. 2001; Namboodiri et al. 2004). However, the role of 
NPM1 in chromatin dynamics and ribosome biogenesis is not fully understood and NPM1 is 
not essential for rDNA transcription (Colombo et al. 2005; Maggi et al. 2008). NPM1 
interacts directly with many cellular proteins and is involved in various cellular processes 
including centrosome duplication and mRNA splicing (Grisendi et al. 2006; Lindstrom and 
Zhang 2006; Okuwaki 2008). NPM1 staining can be used as a control for detecting nucleolar 
stress due to its strong association with the nucleolar rim, upon nucleolar stress induction the 
nucleolus becomes deformed in a way visible with NPM1 staining.  After nucleolar stress 
induction ribosomal proteins (RPs) dissociate from the nucleolus and stabilize p53, this is 
also true for NPM1. NPM1 can directly stabilize p53, bind MDM2 inhibiting its degradation 
of p53 as well as stabilizing ARF leading to increased p53 activation (Fig. 3). It has been 
suggested that NPM1 is essential for the full p53 response (Colombo et al. 2002; Kurki et al. 
2004). However, NPM1 is not the only nucleolar protein capable of mediating p53 
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stabilization following nucleolar stress (Lindstrom et al. 2007; Macias et al. 2010; Zhou et al. 
2012).  
Furthermore, NPM1 interacts with proteins involved in maintaining nucleolar structure. One 
such protein is CTCF, a sequence-specific DNA binding protein that delimits juxtaposed 
domains of active and inactive chromatin (Yusufzai et al. 2004; Zlatanova and Caiafa 2009). 
Its loss results in nucleolar fragmentation and reduced silencing of rDNA (Guerrero and 
Maggert 2011; Hernandez-Hernandez et al. 2012). NPM1 plays another role in maintaining 
DNA integrity during mitosis where it is involved in centrosome duplication. Npm1-/- mouse 
embryonic fibroblasts (MEFs) show centrosome amplification and increased genomic 
instabillity (Grisendi et al. 2005). 
1.5.3 NPM1s dual role in cancer 
NPM1 is frequently mutated in lymphoma and leukemia and found to be overexpressed in 
solid tumors, this suggests a dual role for NPM1 in cancer. High levels of NPM1 may help to 
conserve the structural integrity of nucleolar chromatin, functional rDNA transcription and 
ribosome biogenesis, whereas cells with reduced levels of nucleolar NPM1 or mutant NPM1 
may suffer disruption of nucleolar chromatin organization, blunting of the p53 response and 
genomic instability (Grisendi et al. 2006). 
1.5.3.1 Loss of NPM1 function in cancer 
ARF is a nucleolar protein that binds and antagonizes MDM2 ubiquitin ligase activity for p53 
(Pomerantz et al. 1998; Zhang et al. 1998). In turn, NPM1 co-localizes with and binds ARF 
protecting it from degradation (Korgaonkar et al. 2005). Thus, in the absence of NPM1, ARF 
is unstable and is less effective in activating p53 (Colombo et al. 2005; Colombo et al. 2006). 
In AML, which often exhibits a certain NPM1 mutation (NPM1c+) resulting in NPM1 
localization to the cytoplasm. This would cause a scenario of decreased amounts of NPM1 in 
the nucleolus and lead to the NPM1c+ mediated translocation of ARF from the cell nucleus to 
the cytoplasm thereby preventing its p53 stabilization. AML associated NPM1 mutations 
often overlap with mutations in DNMT3A (TCGA 2013). Loss of function in DNMTs 
(DNMT1/DNMT3B) have been associated with elevated levels of rRNA primary transcript 
(Majumder et al. 2006). 
Depletion of NPM1 in Arf-/- MEFs and HeLa cells can also increase rDNA transcription 
(Apicelli et al. 2008; Maggi et al. 2008; Tafforeau et al. 2013). Npm1-/- cells are suggested 
more predisposed to transformation by oncogenes, such as Myc and Ras. NPM1 together 
with the F-box protein Fbw7γ is involved in the ubiquitination and proteasome degradation of 
c-Myc. Hence, NPM1 loss can stabilize c-Myc and result in enhanced cell growth (Bonetti et 
al. 2008). 
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1.5.3.2 NPM1 upregulation in cancer 
NPM1 is highly expressed in a number of cancers but the functional consequences remain 
unclear (Colombo et al. 2011). In glioma there is evidence of NPM1 upregulation and it is 
reported that loss of NPM1 sensitized U87MG and A172 glioma cells to TMZ resulting in cell 
death and reduced colony formation (Gimenez et al. 2012). NPM1 was found to be critical for 
rDNA transcription in HeLa cells (Murano et al. 2008). 
As discussed earlier gliomas have frequent alterations of pathways concerning p53 and ARF 
rendering the pathways inactive therefore gliomas could instead benefit from the growth 
promoting and chaperone functions of NPM1. Possible benefits of high NPM1 levels could be 
increased resistance to nucleolar stress, increased DNA stability and stable ribosome 
biogenesis. Hence, the ability of NPM1 to suppress apoptosis may promote cancer cell survival 
during tumor development (Grisendi et al. 2006). Furthermore, the possible role of NPM1 in 
histone and DNA modifications makes it interesting to investigate with regards to the suggested 
epigenetic states of gliomas (Brennan et al. 2013). 
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2 AIMS 
The aims of the thesis were: 
I. To generate a library of glioblastoma patient derived cell lines (PDCLs) grown under 
neural stem cell conditions with accompanying patient derived xenografts (PDXs) and 
evaluate these models in contrast to patient tumors. 
II. Investigate Prominin-1 expression in the developing/adult CNS and in glioblastomas using 
RNA based in situ hybridization and evaluate antibody recognition of Prominin-1 expressing 
cells.  
III. Investigate the nucleolar changes induced following NPM1 depletion in relation to 
morphology, chromatin structure and rDNA transcription. 
IV. Investigate the possible roles of NPM1 in gliomas. 
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3 RESULTS AND DISCUSSION 
3.1 PAPER I 
Integrative pathogenomic analysis of a glioblastoma cell line library reveals novel tumor cell 
intrinsic subclass distinctions 
3.1.1 Results 
We cultured 91 glioblastoma samples, 43% of samples processed (39 of 91) generated 
PDCLs with long term growth potential (greater than 5 passages) in non-adherent serum free 
EGF, bFGF supplemented NSC culturing conditions. A subset of these lines were further 
characterized, 22 PDCLs generated from de novo and 5 from recurrent glioblastomas, termed 
BT-lines. BT-lines and their corresponding patient derived xenograft (PDX) recapitulated 
patient tumors, shown by genomic and proteomic analyses. Common glioblastoma genetic 
alteration signatures were preserved including EGFR, PDGFRA, MDM4, CDK4 and CDK6 
amplifications, EGFRvIII, PTEN and CDKN2A deletions and we also noted QKI (tumor 
suppressor) loss and MYC amplifications. BT-lines expressed glial stem/progenitor cell and 
glioblastoma associated proteins NESTIN, SOX2, OLIG2, GFAP confirming their glial 
nature. 
BT-line PDXs did not only grow in an infiltrative pattern similar to that of patient 
glioblastomas but also matched several WHO described histological features of glioblastoma; 
classic, gemistocytic, giant cell, myxoid, oligodendroglial and poorly differentiated. This 
could also be linked back to founding tumors. 
Expression profiling of BT-lines revealed 4 clinically relevant in vitro subclasses; A, B, C 
and D. Class A was associated with Wnt/B-catenin, TGF-B and BMP signaling with 
expression of genes; ACVR1, DKK3, FGFR1, HDAC9, SMAD7, SFRP1 and CAV1. Class 
B displayed a signature characterized by interferon signaling with high expression of; IFIT3, 
IRF9, DOK5, MUC1, IFITM1, OAS1 and TNFSF10. Notch signaling associated genes were 
detected in Class C; DTX1, HEY1, AKT3 and BCL7A. Class D expressed genes involved in 
p53 signaling and cell cycle checkpoints; BIRC5, MAD2L1, MTCH2, PLK4, CHEK2, 
MCM10, MYBL2 and NASP. Subclass comparisons revealed that in vitro BT-line classes 
resembled the TCGA Mesenchymal and Proneural in vivo subclasses, however they were not 
a four-group division of theses two subclasses. Class A most resembled the Mesenchymal 
subclass and class D the Proneural but none of the BT-line classes had strong correlations 
with the Classical and Neural subclasses. Expression profiles of individual BT-lines often 
associated them to several of the TCGA subclasses. BT-lines from recurrent glioblastomas 
destabilized clustering and hence were treated as their own class (class R). 
We investigated correlations between BT-line expression classes, histological features, 
protein levels and genomics. Class A was the one class with no PDXs exhibiting necrosis, 
microvascular proliferation (MVP) or hemorrhage. Class B lacked CDKN2A deletions, which 
might be subsidized with RB1 loss and subsequent mRNA down regulation (-2.9 in relation 
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to the rest of the BT classes) seen in this subclass. In Class B SOX2 was the most dominant 
IHC marker and PDXs had infiltrative growth patterns. BT-lines displaying a combination of 
giant cell and poorly differentiated histology did not have CDKN2A deletions despite 
belonging to different expression classes.  
EGFRvIII deletions were found in class C and D, the EGFRvIII deletion was accompanied by 
a classic glioblastoma histology in 4/4 cases and round cell / oligo histology in 3/4 cases, 
EGFR amplification was seen in all classes except B. The one BT-line with PDGFRA 
amplification fell within class D, which was the one closest resembling the Proneural 
subtype. Class C gave rise to highly infiltrative xenografts while class D and R showed the 
highest presence of fast growing more stationary tumors possibly due to deranged regulation 
of cell cycle genes for class D and the selective pressure of previous treatment in class R. 
SOX2 which has been suggested as a driver in glioblastoma was present in all BT-lines, there 
was however differences in its relation to other proteins. High SOX2 and OLIG2 seemed to 
be associated with class C (Notch signaling) while high SOX2, GFAP and NESTIN was seen 
in class D (p53 signaling and cell cycle). The same pattern was seen within class R with 
SOX2 /OLIG2 high in some BT-lines and SOX2/GFAP in others. Class R showed the 
highest levels of pAKT. Both pAKTThr308 and pAKTSer473 was significantly higher in BT-lines 
generated from recurrent compared to BT-lines generated from de novo glioblastomas. 
We applied the top genes defining in vitro subclasses from de novo glioblastomas to TCGA 
patient tissue sample data, which generated 5 subclasses with differences in survival. Class 3 
defined a group of patients that were older and had shorter survival. This was independent of 
IDH1 mutational status and if the tumor was recurrent or not. Although the decrease in 
survival can be explained by the higher median age, class 3 identifies a biologically relevant 
group of older patients. Class 3 closest resembled BT-line class B and top upregulated genes 
in class 3 are involved in mitochondrial respiration, oligodendrocyte density, the BRCA1 
network and genes often down regulated in Alzheimer’s disease. 
3.1.2 Discussion 
This investigation of glioblastoma cell dynamics in vitro and in vivo demonstrates PDCLs 
and accompanying PDXs as a truly heterogeneous glioblastoma model concerning tumor cell 
intrinsic features and highly relevant for functional studies and drug screens. 
Glioblastoma PDCLs cultured in NSC conditions and their PDXs are reported to represent 
the patient disease to a higher extent than PDCLs grown long term in serum culturing 
conditions (Bigner et al. 1990; Singh et al. 2004; Gunther et al. 2008). Our BT-line library 
proves this concept and further strengthens the notion that PDCLs to a very high extent, 
recapitulate the original disease. BT-lines glial origin could be confirmed using IHC leaving 
no doubt that these PDCLs were glioblastoma derived. PDXs grew in infiltrative manner and 
recapitulated several WHO described histological subtypes and features characteristic for 
glioblastoma pathology. The feature that was most under-represented in PDXs was MVP, 
which normally is one of the criteria in the diagnosis of glioblastoma. This needs 
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consideration if one sets out to investigate tumor-vasculature interactions in a PDX model. 
We can only speculate if the lack of MVP is a consequence of the interspecies, 
immunodeficient or spatial setting in PDX models.   
The genomic landscape in BT-lines matched that described for glioblastomas (Brennan et al. 
2013). The lack of amplifications conserved in serum cultured lines has been one of the main 
issues with those models (Bigner et al. 1990). EGFR amplifications were found in 38% of 
BT-lines and 44% of those carried the EGFRvIII deletion. This, including the retention of 
PDGFRA, MDM4, CDK4 and CDK6 amplifications will hopefully provide models applicable 
for developing therapies targeting these alterations. Genetic events rare in glioblastomas were 
seen to an even lesser extent in BT-lines, this would most likely be due to the limited number 
of BT-lines included in our study. Nonetheless, there could be an in vitro selection. There did 
appear to be enrichment for CDKN2A deletions, although this was not statistically significant. 
CDKN2A deletion has been associated with the enhanced ability to grow in cell culture 
(Hartmann et al. 1999). However, it was not a feature required for BT-lines as seen in class B 
with normal CDKN2A karyotype, although mutational status was not assessed. 
Glioblastomas have been reported to consist of different cell populations with different 
amplified genes, such as EGFR, PDGFR and MET (Snuderl et al. 2011). Unfortunately we 
have not yet investigated this in BT-lines, however it would be of interest to know if this also 
could be sustained in PDCLs. Tumor heterogeneity and inter clonal cooperation have been 
proposed to promote disease progression. Heterogeneity is also described in regards to 
mRNA expression classes. Single cell sequencing showed that glioblastomas could harbor 
tumor cell populations representing all of the TCGA described expression subclasses (Patel et 
al. 2014). This raises the question of how valid TCGA expression subclasses are and suggests 
that differences seen in subclasses would just be dependent on what tumor region that was 
analyzed. The heterogeneity is also an issue in BT-lines, however due to reports that PDCLs 
grown in NSC conditions become devoid of non-tumor cells after 3-5 passages this should 
eliminate non-tumor cell contribution to expression profiles. With regards to this we were 
hoping that expression profiling of the BT-line library would reveal tumor cell intrinsic 
pathways activated in gliomas with greater biological value than those based on tissue 
samples. 
We ended up with four BT-line subclasses after removing recurrent samples from the 
analysis. Recurrent samples destabilized the clustering so due to the logical conclusion that 
these samples might represent a different biology they were removed. The accuracy of doing 
so can be argued since if they would represent a similar biological divergence due to being 
from recurrent samples they should have clustered into their own class giving us 5 distinct 
subclasses. Either way, using PDCLs from de novo glioblastomas generated four subclasses. 
It was not so surprising to see that two of the BT-line subclasses (C and D) were associated 
with the Proneural subclass given the SOX2, OLIG2 and NSC associations of PDCLs. It was 
more unexpected to see that the Mesenchymal subclass correlated most with the other two (A 
and B) since it has been suggested that the Mesenchymal TCGA subclass could be associated 
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with inflammatory cells (Verhaak et al. 2010). We also saw high levels of TGF-B associated 
genes in BT-line class A suggesting that there is in fact a tumor cell intrinsic activation of this 
pathway and it is not a byproduct of inflammatory cells. Another surprise was the lack of a 
strong resemblance to the Classical subclass despite the retention of EGFR amplifications in 
BT-lines. This could be due to the addition of EGF in our cell cultures, canceling out 
differences in levels of EGFR signaling between different BT-lines. It could also be so that 
this is not the defining factor of that subclass since EGFR amplification is also found in other 
TCGA subclasses. BT-lines do give us a unique set of expression subclasses, both with 
similarities and distinctions from TCGA subclasses. 
Interestingly, class R showed the highest levels of pAKT. Both pAKTThr308 and pAKTSer473 
was significantly higher in BT-lines generated from recurrent compared to BT-lines 
generated from de novo glioblastomas. Implying increased AKT signaling, which has been 
linked to faster tumor recurrence and more aggressive tumors (Johnson et al. 2014; Robinson 
et al. 2014). This would suggest that mechanisms causing this increased AKT signaling are 
preserved in PDCL models. Hence, collections of BT-lines derived from recurrent tumors 
represent a system for addressing the recurrent disease specifically.    
In order to investigate if our BT-line classes could add any insight to or stratification of 
clinical samples BT-line class defining genes where applied to the TCGA patient dataset. 
This led to further stratification of TCGA clinical samples and the isolation of subclass 3 
defining a set of patients that were older and had a shorter survival not identified using the 
TCGA subclassification. Using in vitro PDCLs from glioblastomas to determine tumor cell 
intrinsic properties would then better describe the patient diseases than bulk tissue samples 
from the tumor. 
Our cohort of PDCLs shows a great diversity with many key aspects of glioblastoma present. 
The main issue with further research using this model system will be to determine how many 
PDCLs of a given sort are needed for relevant studies i.e. how many PDCLs with the 
EGFRvIII variant are needed in order to evaluate a drug acting on said target. This will be 
dependent on what one decides to study, certain processes in the cell will be more or less 
redundant and my personal guess is that often one will need to target multiple pathways 
simultaneously. This will increase the number of PDCLs needed in order to target different 
constellations of activated pathways. It also remains to be determined if PDCLs will need to 
be investigated in vivo as PDX models in order for them to produce relevant results. Despite 
not recapitulating the true human physiology PDXs may add that extra degree of metabolic 
and microenvironment impact needed to better evaluate new drug treatments. There is also 
the issue of some PDCLs only being expandable in vivo. PDX models will be more expensive 
but regarding our limited understanding of microenvironment, metabolism, drug target 
availability and cancer cell interactions this might help us to better mimic the disease until we 
can grasp all concepts needed to fully construct relevant in vitro models. 
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3.2 PAPER II 
Prominin-1 (CD133) defines both stem and non-stem cell populations in CNS development 
and gliomas 
3.2.1 Results 
In order to get more clarity in the expression patterns of Prominin-1 in embryonic/adult CNS 
and glioblastoma we utilized RNA in situ hybridization as complement to existing Prominin-
1 targeting antibodies.  
Using RNA in situ hybridization tools capable of detecting multiple isoforms of Prom1, we 
find evidence for two distinct Prom1 cell populations in mouse brain. Prom1 RNA is 
expressed in stem/progenitor cells of the ventricular zone and the spinal cord in embryonic 
brain. In adult mouse brain Prom1 RNA is high in a rare widely distributed cell population 
(Prom1hi) and low in SVZ/SGZ stem cell zones. Prom1hi cells are found in both white and 
gray matter but there is a higher occurrence in white matter, reconfirmed by WB and qRT-
PCR. Lineage marker analysis reveals that Prom1hi cells predominantly co-label with Olig2 
(98%) there is however a subset of Prom1hi cells expressing Sox2 (10%). Olig1/2 knockout 
mice retain Prom1hi cells so unlike other Olig2 expressing cells Prom1hi are not dependent on 
Olig gene function. Bromodeoxyuridine (BrdU) labeling identifies Prom1hi as a slow-
dividing/slowly generated cell population in the adult brain. The Prom1hi population shows 
no increase in BrdU labeling after mechanical lesioning of the brain, neither does this cell 
population decrease or increase after irradiation.  
PROM1 could also be identified in the human embryonic VZ and in cultured NSCs from the 
embryonic ganglionic eminence. In adult human brain, PROM1 cells are rarely positive for 
OLIG2, but express astroglial markers GFAP and SOX2. There is a large variability of 
PROM1 protein levels in our human glioblastoma PDCLs/PDXs library, from no expression 
to strong uniform expression. PROM1 is associated with GFAP, SOX2 and OLIG2 however 
association patterns vary across PDCLs. PROM1 populations can both be predominantly 
senescing or actively dividing as illustrated by Ki67 labeling. TCGA and PDX data show that 
high expression of PROM1 correlates with poor overall survival in the Proneural subclass. 
Within clinical samples of the TCGA Proneural subclass, high PROM1 expression correlates 
inversely with IDH1 (R132H) mutation.  
3.2.2 Discussion 
Prominin-1 has been heavily debated as to its validity as a stem cell/cancer stem cell marker. 
Despite this I would argue that the Prominin-1 is very interesting in regards to glial cell 
development and differentiation. Prominin-1 is reported in multiple glial cell types; during 
development it has been associated with VZ regions and stem cells (Corbeil et al. 2009). In 
the adult it has been described in SVZ GFAP/EGFR positive stem cells but also in ependymal 
cells and the myelin sheaths of oligodendrocytes (Corbeil et al. 2009; Codega et al. 2014; 
Khatri et al. 2014). 
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Our results support the role of Prominin-1 as a stem/progenitor cell marker in the embryonic 
brain. However, during postnatal brain development (between P0-P14) there is an expression 
shift with decreased levels in SVZ/SGZ and Prom1 is now found in a distributed population 
of Prom1hi cells. In the mouse brain this cell population is maintained in the adult and is 
mainly associated with Olig2. This raises the possibility that the Prom1hi population is in fact 
myelinating oligodendrocytes.  
Since we can determine that Prom1hi cells are slowly cycling or generated, due to BrdU 
labeling, this is a dynamic population of cells. They do not respond to mechanical lesioning 
of the brain as described for the NG2+ cell and SVZ stem/progenitor cells (Buffo et al. 2005; 
Dimou et al. 2008), nor did irradiation ablate Prom1hi cells. Cycling NG2/Olig2 positive 
oligodendrocyte progenitors are abundant in the adult mouse brain but the low number of 
BrdU labeled Prom1hi cells and lack of co-staining for NG2 distinguishes them from this 
population. However, the possibility remains that NG2+ cells are related to these Prom1hi 
cells due to the Olig2 relation. NG2+ progenitor cells are dependent on Olig2 functions and 
are ablated in Olig1/2 knock-out mice, which subsequently results in lack of oligodendrocytes 
and embryonic lethality (Ligon et al. 2006). This is not the case for Prom1hi cells, we also 
identify a subpopulation of Prom1hi cells expressing Sox2. This suggests that they are not 
typical oligodendroglial cells.  
Even though we detected lower Prom1 expression in the SVZ compared to that of Prom1hi it 
does not oppose the role of Prom1 in stem cells of the adult mouse SVZ, there could simply 
be a lower level expressed in these cells compared to the Prom1hi cells. Neither do our results 
rule out the possibility that Prom1hi cells are quiescent non-cycling stem cells that retain the 
capability to re-enter the cell cycle and self renew which has been described for Prom1 
expressing cells in the SVZ (Codega et al. 2014; Khatri et al. 2014). As it has been reported 
that there might be a distinction in the splice variants between oligodendrocytes, expressing 
s.3, and embryonic stem cells expressing s.1 (Corbeil et al. 2009), it would be interesting to 
investigate possible similarities in the adult brain. This could lead to further distinction 
between the Prom1hi, Prom1 SVZ, Olig2 and Sox2 subpopulations.  
The Prom1hi cells appear to be identical to cells previously identified as neural stem cells in 
the early postnatal cerebellar white matter (Lee et al. 2005), but highlights that they are 
present throughout the entire CNS also in the adult brain. The question still remains however 
if those were real stem cells due to the fact that they were isolated using FACS and then 
assumed to be stem cells because the end result was cells from different lineages. I do not 
believe FACS sorting to be specific enough to make such a conclusion. Another issue is that 
whole cerebellum was used that could possibly hold Prom1+ SVZ stem cells in the 
developing fourth ventricle.  
In the human we could not follow the developing brain to the same extent as in the mouse. 
We do find PROM1 expression in the ventricular zone and NSC cultures of the embryonic 
human brain. NSC cultures show a homogenous staining pattern of PROM1 mRNA and 
protein making it very hard to associate with specific lineage markers. In the adult we again 
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find a distributed cell population expressing PROM1, but in the human brain it is associated 
with GFAP and SOX2 rather than OLIG2. Here there is also a presence of PROM1 cells in 
the SVZ that co-localize with the stem cell marker GFAPδ. As in the mice PROM1 is 
detected on the ependymal cells apical surfaces and microvilli in humans. 
Our results regarding PROM1 in glioblastoma further indicated that it should not be referred 
to as a marker expressed in only a minor subpopulation of cancer stem cells, as previously 
suggested (Singh et al. 2003; Singh et al. 2004). In our glioblastoma PDCL/PDX models we 
find varying levels of PROM1, from very high homogenous to low single cell expression. 
PROM1 again co-labels with SOX2 and GFAP but now to higher extent also with OLIG2. 
PROM1 association to GFAP, OLIG2 and Ki67 was found to be the complete opposite in 
different PDCLs. Using TCGA glioblastoma patient and BT-line expression data we did not 
detect a strong association of PROM1 with other stem cells genes. This included use of 
methods for RNA expression profiling, RISH, and IHC. This makes it hard to assign PROM1 
cells to a certain cell state and suggest that PROM1 is tied to only cancer stem cells. 
However, independent of its relevance as a CSC marker, PROM1 seems to be associated with 
a clinically relevant biology in glioblastoma. Multiple studies have shown PROM1 antigen or 
PROM1 mRNA expression to be associated with shorter survival in patients (Beier et al. 
2007; Zeppernick et al. 2008; Laks et al. 2009). In the Proneural expression subgroup 
PROM1 is found to be associated with shorter survival. Examining TCGA clinical samples 
we find that PROM1 expression is anti-correlated with IDH1 (R132H) mutation, which 
supports a different biology for IDH1 mutant tumors versus glioblastomas with wild type 
IDH1. This anti correlation with IDH1 mutation would also explain the worse prognosis of 
high PROM1 in glioblastomas. 
The role of Prominin-1 as a stem cell marker continues to elude us. We offer several insights 
into the glial nature of Prominin-1 cells and discover that there are key differences in human 
and murine systems. Prominin-1 plays a role in glioblastoma biology but what that exact role 
is remains to be determined. 
3.3 PAPER III 
Loss of nucleolar histone chaperone NPM1 triggers rearrangement of heterochromatin and 
synergizes with a deficiency in DNA methyltransferase DNMT3A to drive ribosomal DNA 
transcription 
3.3.1 Results  
NPM1 depleted cancer cells and normal fibroblasts displayed deformed nucleoli and a 
rearrangement of perinucleolar heterochromatin. We found that NPM1 associated with HP1γ 
and is required for perinucleolar tethering of HP1γ foci. NPM1 is enriched, and juxtaposed, to 
heterochromatin in the nucleolar periphery marked by H3K9me3/HP1γ. In addition to HP1γ 
we found NPM1 to interact with the core histones and linker histone H1.5. Depletion of 
NPM1 displayed a modest decrease in H3K9 di- and tri-methylation at the rDNA promoter 
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but not at total cellular levels. Despite the apparent changes in nucleolar morphology there 
was no decrease in rDNA transcription. Neither did depletion of NPM1 cause p53 activation 
instead it partially abrogated the p53-dependent increase in p21, WIG1 and PUMA in 
response to actinomycin D or 5-FU treatment in U2OS cells. Along with these results cell 
proliferation was sustained in cancer cells and only slightly decreased in normal fibroblasts 
after NPM1 depletion. Furthermore, co-depletion of both DNA methyltransferase DNMT3A 
and NPM1 enhanced rDNA transcription, this was accompanied by a normalization of 
nucleolar morphology.   
3.3.2 Discussion 
NPM1 is a nucleolar chaperon protein involved in a number of processes from nucleolar 
stress, ribosome biogenesis to genome stability, all relevant to cancer (Grisendi et al. 2006). 
As we described here NPM1 also has a role in maintaining the general structural organization 
of the nucleolus and its surrounding chromatin. Even partial reduction of NPM1 levels 
resulted in a distorted nucleolar structure accompanied by perinucleolar heterochromatin 
rearrangement. Despite this we observed no major effect on rDNA transcription after 
depletion of NPM1 in cancer cells, which is perhaps logical since one can generate mouse 
embryonic fibroblasts (MEFs) that lack Npm1 as long as it is in combination with loss of 
p53. Normal human diploid fibroblasts do however show a slight reduction in cell 
proliferation rate after NPM1 depletion. 
We could identify several NPM1 interacting proteins in glioma cell line U1242MG. Among 
those were several related to heterochromatin formation (H3, H1.5, HP1γ). Formation of 
heterochromatin is crucial for maintaining nucleolar structure and the integrity of rDNA 
(Guetg and Santoro 2012). This led us to further investigate the role of NPM1 in organization 
of the perinucleolar chromatin.  
In Drosophila H1 is required for the structural integrity of heterochromatin and maintenance 
of pericentric heterochromatin-associated histone marks, including H3K9me2 (Lu et al. 
2009), and loss of H3K9 methylation induces fragmentation of the nucleolus due to 
illegitimate recombination of repetitive DNA sequences (Peng and Karpen 2007). In NPM1 
depleted cells we did see a reduction of H3K9 di- and tri-methylation at the rDNA promoter. 
However the question remains if these levels of reduction would be sufficient to alone cause 
the change in nucleolar morphology. We also identified HP1γ as a novel NPM1 associated 
protein in the perinucleolar region. NPM1 was required for efficient tethering of HP1γ to the 
nucleolus. HP1γ is localized to both euchromatin and heterochromatin, and is enriched in 
perinucleolar chromatin (Schmiedeberg et al. 2004). HP1γ is involved in maintaining normal 
nucleolar morphology based on its role in heterochromatin formation (Larson et al. 2012). 
Depletion of other proteins involved in rDNA silencing and/or heterochromatin formation 
such as DNMT1, HP1, SIRT1, and the histone H3K9 methyltransferase SUV39H1 also 
induces alterations in the nucleolar structure (Espada et al. 2007; Peng and Karpen 2007; 
Salminen and Kaarniranta 2009; Horakova et al. 2010). Thus, it is plausible that the effects 
we see after NPM1 depletion is due to a similar inability to maintain ordered heterochromatin 
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structure. Since NPM1 interacts with multiple proteins involved in this it may also here act as 
a type of chaperone, assisting in protein shuttling as well as further promoting 
heterochromatin stability.  
A decrease in rDNA methylation results in abnormal rDNA transcription and disorganized 
nucleoli (Espada et al. 2007). Similarly, depletion of ribosomal proteins affects ribosomal 
biogenesis and nucleolar chromatin organization (O'Donohue et al. 2010). However, NPM1 
was not essential for rDNA transcription in the U1242MG cell line, this is also observed in 
other cell lines (Colombo et al. 2005; Maggi et al. 2008), nor is NPM1 localized to the 
fibrillarin rich regions of nucleoli where active rDNA transcription takes place. Despite not 
directly affecting rDNA transcription absence of NPM1 may create a permissive environment 
allowing for additional epigenetic changes. Mutations in DNMT3A and NPM1 are often co-
occurring in AML (TCGA 2013). Loss of DNMT1/3B function results in decreased rDNA 
methylation followed by increased abnormal transcription of rDNA copies and disorganized 
nucleoli (Majumder et al. 2006; Espada et al. 2007). Here we could show that co-depletion of 
NPM1 and DNMT3A synergized to enhance rDNA transcription. This would fit with our 
previous results suggesting a decrease in heterochromatin stability and reduction of H3K9 
methylation already induced by NPM1 depletion.  
We propose that NPM1 plays a crucial role in the structural integrity of the nucleolus. This is 
possibly due to NPM1 being involved in many of the processes concerning heterochromatin 
formation and its organization around the nucleolus.  
3.4 PAPER IV 
Expression and cellular localization patterns of the histone chaperone NPM1/nucleophosmin 
in glioma 
3.4.1 Results 
In this study, NPM1 was detected by immunohistochemistry in a cohort of human astrocytic 
gliomas of different grades. NPM1 was expressed in all tumors with the highest staining 
intensity in grade IV tumor samples. NPM1 was localized to both the nucleolus and the 
nucleoplasm in grade IV tumors, a distribution also seen in glioblastoma cell lines. Lower 
grade tumors predominantly presented with nucleolar staining, however with enlarged 
nucleoli. We demonstrate that NPM1 is required to maintain the structure of the nucleolus in 
glioma cells, confirming the role of NPM1 in nucleolar morphology described in our previous 
study. Depletion of NPM1 had modest effects on the viability and proliferation rate of 
U251MG, U1242MG, and U343MGa Cl2:6 glioblastoma cell lines. When cells were 
exposed to chemotherapeutic agents following NPM1 depletion we found that U251MG cells 
were sensitized to cell death induced by temozolomide (TMZ) and 5-Fluorouracil (5FU). 
Previously we identified linker histone H1.5 as an NPM1 associated protein in glioma cells. 
Here we demonstrate that depletion of NPM1 also sensitized glioma cells to reduced levels of 
H1.5 leading to the increased detection of cleaved caspase-3 (CC3) and cell death. 
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3.4.2 Discussion 
Since NPM1 is abundant in solid tumors it was of interest for us to determine the expression 
patterns and explore the functions of NPM1 in gliomas. The role of NPM1 in cancer remains 
complex with both growth promoting and tumor suppressive functions ascribed to NPM1 
(Grisendi et al. 2006). Our findings of high NPM1 levels in astrocytic gliomas suggest that 
NPM1 may suppress apoptosis or play some other significant pro-survival role in gliomas. 
Further, the increase seen in glioblastomas might implicate a role in tumor progression.  
NPM1 interacts with a number of different proteins that may be involved in the organization 
of chromatin such as core histones and linker histone H1.5, shown by us and others (Park et 
al. 2010; Gadad et al. 2011; Holmberg Olausson et al. 2014). Linker histone H1 isoforms are 
best known for their ability to stabilize condensed higher-order chromatin structures and H1 
has been shown to interact with a large network of nucleolar proteins (Kalashnikova et al. 
2013). NPM1 and H1.5 interactions have been shown by us and others (Gadad et al. 2011; 
Holmberg Olausson et al. 2014). H1.5 depletion causes upregulation of genes involved in cell 
death/apoptosis and reduced cell growth (Li et al. 2012). We found that NPM1 reduction 
sensitized glioma cells to cell death triggered by a deficiency in H1.5, further linking 
NPM1and H1.5 function. 
Depletion of NPM1 sensitizes U87MG and A172 glioma cells to TMZ (Gimenez et al. 2012). 
This was confirmed by us in U251MG cells where NPM1 depletion resulted in sensitization 
to TMZ and 5-FU. However the same was not as apparent for U1242MG and U343MGa 
Cl2:6 cells, although a similar trend was observed. The different glioblastoma cell lines had 
similar initial sensitivity to TMZ and 5-FU, except U343MGa Cl2:6 that was less sensitive to 
5-FU, so it would appear that the increase in sensitivity seen in U251 is dependant on the loss 
of NPM1. 
While our results demonstrate a link between NPM1 and linker histone H1.5 in the regulation 
of cell death it remains to be determined how this occurs. Since NPM1 depletion sensitizes 
glioma cells to TMZ/5FU it might be suggested that this is due more to accumulated targeting 
of DNA integrity rather than a specific loss of function as a consequence of lost NPM1/H1.5 
interaction, however this remains to be determined. Strongest effect was seen in U251MG 
cells which appear to have increased aneuploidy compared to U1242MG and U343MGa 
Cl2:6. Hence, it would be interesting to test more cell lines where this features could be 
compared in relation to NPM1. NPM1 is relevant for DNA integrity and centrosome 
function, which could be a greater issue in cancer cells with increased aneuploidy. 
Naturally one would like to investigate these effects on more cell lines including glioma cells 
represented by PDCLs cultured under NSC conditions. The MG-lines used in these 
experiments are very resistant to TMZ and 5-FU, forcing us to use very high concentrations 
in order to see effects. In addition we would seek to further describe the events/pathways 
resulting in cell death upon NPM1/H1.5 co-depletion.  
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In summary, NPM1 was detected in astrocytic gliomas of all grades with glioblastomas 
displaying the highest levels. Glioblastomas had both nucleolar and nucleoplasmic 
localization of NPM1 also seen in glioblastoma cell lines, in contrast to the predominant 
nucleolar staining in lower grade tumors. Although our studies would suggest little 
effectiveness of targeting NPM1 alone there could be potential in using this as a combination 
treatment. 
4 CONCLUSIONS AND PERSPECTIVES 
Glioblastoma is a truly devastating disease with short survival and no cure despite 
multidisciplinary treatment regimes. To make matters worse the radiotherapy and 
chemotherapy regimens practiced, despite the good intention of aggressively treating the 
tumor, in the end reduces patient quality of life with little benefit in survival (Malmstrom et 
al. 2012). There can also be adverse effects of chemo/radiotherapy with an induction of 
mutations, which might result in increased malignancy (TCGA 2008; van Thuijl et al. 2015). 
The progress in patient survival seen during the last decades appear to be due to better 
surgery and post surgery care rather than new molecular biology strategies devised for 
glioblastoma treatment. Current high throughput molecular screens have done little more than 
reconfirm known genetic events already described for glioblastoma. However, there are also 
new mutations and molecular pathways revealed which may help develop new treatments. 
The popularity boom of cancer stem cells resurfaced the old idea that cancer biology can be 
compared to developmental biology. Even if there still are no reliable cancer stem cell 
markers for glioblastoma it has had a positive influence on how we now view and (try to) 
understand developmental/differentiation pathways and their roles in cancer. The latest in 
cancer is heterogeneity, like cancer stem cells this is an old theory that gained new interest. 
This is a key feature of glioblastoma biology where there is plenty of evidence of a very 
heterogeneous nature. Unfortunately our new growing knowledge base holds no real clinical 
value for today’s glioblastoma patients. We are now better at stratifying patients using IDH1 
mutation status. But that seems to be about it, and it doesn’t really do much difference in the 
end. 
In this thesis we first address one important shortcoming in the glioma (and whole cancer) 
field, the lack of fully representative cancer cell models. Earlier research has spent much time 
on cell lines unable to fully represent glioblastomas. Our work describes the generation of a 
PDCL/PDX library with great potential for further preclinical drug development.   
In the second paper we further elucidate the complex expression patterns of Prominin-1 in the 
developing/adult brain and glioblastoma. Prominin-1 is perhaps one of the cancer stem cell 
markers that have gotten most publicity. Cancer stem cells (CSCs) remain a controversial 
field and our study, like many others, has done little to make it less so. Detecting it in both 
stem and differentiated cells we highlight the very context dependent relationship between 
Prominin-1 and cell state. To make matters even more complicated we find that Prominin-1 
associates with different cell lineage markers in mice and humans. This is perhaps nothing 
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new in regards to glial cell biology, but serves as a reminder for us and others in the field. 
CSCs have been described as an almost mythical cell population responsible for tumor long-
term growth and recurrence after treatment. Only as few as 5-10% of the tumor cells are said 
to be CSCs but in reality… no one knows. 
In the third and fourth study we identify a high abundance of the nucleolar chaperone NPM1 
in glioma cells. Depletion of NPM1 destabilizes the nucleolus and potentiates the effect of 
current treatments available for glioblastoma. Our results here are interesting, for suggesting 
NPM1 as a possible drug target for glioblastoma treatment but also for implying a role for the 
nucleolus in glioma biology. The nucleolus is our ribosome factory and the concept of 
“nucleolar stress” is bound to play interesting roles in cancer.  
All in all, there is no easy solution when it comes to glioblastoma. With increased knowledge 
of the complex biology behind the disease new treatment possibilities will arise. Our work, as 
others, highlights the very diverse features deregulated in a single cancer type. This is where I 
believe today’s research falls short, in addressing the plasticity of cancer cells. Cancer is a 
true evolutionary survivor and our limited understanding of cancer biology makes it very hard 
for us to design new treatments. I rather propose a “blind casting technique”, concentrating 
efforts at constructing relevant cancer models, such as PDCLs/PDXs, and start testing all 
possible drugs available hopefully leaving us with something that actually works.
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